<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        21-883-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEPAKINE 500MG TABS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALPROATE SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        32.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sanofi-aventis, S.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sanofi-aventis, S.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis FRANCE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AG01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: ANTIEPILEPTIC &ndash; ATC code: N03AG01.<br />DEPAKINE belongs to a family of medicines called antiepileptics.<br />This medicine is used to treat various types of epilepsy in adults and children over 6 years of age. It is also used in children to prevent fever-related seizures.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take DEPAKINE 500 mg gastro-resistant tablets</strong><br />&bull;if you are pregnant, unless no other epilepsy treatment works for you (see below &ldquo;Pregnancy, breast-feeding and fertility &ndash; Important advice for women&rdquo;),<br />&bull;if you are a woman of childbearing age, unless no other epilepsy treatment works for you and you are able to follow all the measures of the pregnancy prevention plan (see below &ldquo;Pregnancy, breast-feeding and fertility &ndash; Important advice for women&rdquo;),<br />&bull;if you are allergic to the active substance (sodium valproate) or any of the other ingredients of this medicine (listed in section 6),<br />&bull;if you are allergic to a medicine in the same family as valproate (valproate semisodium, valpromide),<br />&bull;if you have liver disease (acute or chronic hepatitis),<br />&bull;if you or a member of your family have ever had serious liver disease, particularly related to use of a medicine,<br />&bull;if you have hepatic porphyria (hereditary liver disease),<br />&bull;if you have a genetic problem causing a mitochondrial disorder (e.g. Alpers-Huttenlocher Syndrome),<br />&bull;if you have a known metabolic disorder, such as a urea cycle disorder (see &ldquo;Warnings and precautions&rdquo;),<br />&bull;if you have a carnitine deficiency (a very rare metabolic disease), which is not being treated,<br />&bull;if you are currently taking the following medicine:<br />St. John&rsquo;s Wort (plant used to treat depression).<br /><strong>Warnings and precautions</strong><br />This medicine can, in very rare cases, cause liver damage (hepatitis) or pancreas damage (pancreatitis), which can be serious and life-threatening.<br />Your doctor will prescribe blood tests to regularly monitor your liver function, particularly during the first 6 months of treatment.<br /><strong>Inform your doctor immediately if any of the following signs appear:</strong><br />&bull;sudden fatigue, loss of appetite, exhaustion, drowsiness, swelling of the legs, general malaise,<br />&bull;repeated vomiting, nausea, stomach or bowel pain, yellow colour of the skin or eyes (jaundice),<br />&bull;recurrence of epileptic seizures even though you are taking your treatment correctly.<br />&bull;The risk of liver damage is increased if DEPAKINE is given to children under 3 years of age, people taking other antiepileptic drugs at the same time, or people with another neurological or metabolic disorder and severe forms of epilepsy.<br />&bull;If, during treatment with DEPAKINE, you or your child experience(s) problems with balance and coordination, feeling of lethargy or decreased alertness or vomiting, tell your doctor immediately. This may be due to an increased amount of ammonium in the blood.<br /><strong>Talk to your doctor before taking this medicine</strong><br />&bull;If you have kidney disease (renal failure).<br />&bull;If you have systemic lupus erythematosus (rare disease).<br />&bull;If you know or if your doctor suspects that there is a genetic problem caused by a mitochondrial disease in your family, due to a risk of damage to your liver.<br />&bull;If you are suspected of suffering from metabolic disorders, including hereditary disorders caused by an enzyme deficiency of the &ldquo;urea cycle disorder&rdquo; type, due to a risk of increased ammonium levels in the blood.<br />&bull;If you suffer from a rare disease (hereditary metabolic disease) called &ldquo;carnitine palmitoyltransferase II deficiency&rdquo;, because you have an increased risk of serious muscle disorders (rhabdomyolysis).<br />&bull;If you have a dietary deficiency of carnitine, which is contained in meat and dairy products, especially in children under 10 years of age.<br />&bull;If you have a carnitine deficiency and you are taking carnitine.<br />&bull;If you are scheduled to have surgery, you must inform the medical personnel that you are taking this medicine.<br />&bull;At the start of treatment, your doctor will check that you are not pregnant and that you have a method of contraception (see &ldquo;Pregnancy&rdquo;).<br />&bull;As with other antiepileptics, taking this medicine can lead to your seizures worsening or becoming more frequent; you may even experience a different type of seizure. If this happens, immediately consult your doctor.<br />&bull;This medicine can cause weight gain. Your doctor will recommend that you take certain dietary measures and will monitor your weight.<br />&bull;Self-destructive or suicidal thoughts have also been observed in a small number of people treated with antiepileptics such as DEPAKINE. If you have these kinds of thoughts, contact your doctor immediately.<br />&bull;Inform your doctor if you have symptoms such as tremor, stiffness of the limbs and difficulty walking (extrapyramidal disorders) or memory and mental capacity disorders. He or she will try to find out whether they are caused by an underlying disease or by DEPAKINE 500 mg gastro-resistant tablets. It may be necessary to stop treatment.<br />Inform your doctor if your child is taking another antiepileptic treatment or has another neurological or metabolic disease or severe forms of epilepsy.<br /><strong>Other medicines and DEPAKINE 500 mg gastro-resistant tablets</strong><br />Some medicines may alter the effects of valproate and vice versa.<br /><strong>You must never take this medicine if you are taking the following medicine:</strong><br />&bull;St. John&rsquo;s Wort (plant-based medicine used to treat depression).<br />Unless your doctor or pharmacist tells you otherwise, you must not take this medicine if you are taking, have recently taken or might take the following medicines:<br />&bull;Lamotrigine (another medicine used to treat epileptic seizures);<br />&bull;Penems (carbapenems) (antibiotics used to treat bacterial infections).<br /><strong>Tell your doctor if you are taking:</strong><br />&bull;acetazolamide-containing medicines (medicines used to lower eye pressure or carbon dioxide levels in the blood).<br />&bull;antibiotics (medicines containing aztreonam or rifampicin).<br />&bull;other antiepileptic medicines (medicines containing carbamazepine, felbamate, phenytoin, fosphenytoin, primidone, phenobarbital, rufinamide, topiramate or zonisamide).<br />&bull;nimodipine: DEPAKINE can increase the effects of nimodipine (medicine used to prevent complications that can occur after bleeding in the brain).<br />&bull;oestrogen-containing products (including some birth control pills).<br />&bull;propofol (anaesthetic medicine).<br />&bull;zidovudine-containing medicines (medicines used to treat HIV infection (Human Immunodeficiency Virus)).<br />&bull;medicines containing lithium (medicines used to treat mood disorders);<br />&bull;medicines containing metamizole (medicines used to treat pain and fever);<br />&bull;methotrexate (used to treat cancer and inflammatory diseases);<br />&bull;salicylates (including aspirin);<br />&bull;cannabidiol (used to treat epilepsy and other illnesses);<br />&bull;some anti-infectives containing pivalate (for example: pivampicillin, adefovir dipivoxil).<br />Specifically in children under 3 years of age, you must avoid giving medicines containing salicylates (including aspirin) during treatment.<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br /><strong>DEPAKINE 500 mg gastro-resistant tablets with food, drink and alcohol</strong><br />Use of alcoholic beverages is not recommended during treatment with DEPAKINE.<br /><strong>Pregnancy, breast-feeding and fertility<br /><u>Pregnancy</u></strong><br /><strong>Important advice for women:<br />Valproate is harmful to unborn child if taken during pregnancy. Therefore:<br />&bull;If you are a female child, female adolescent or woman of childbearing age, your specialist doctor may not prescribe valproate for you unless other treatments are ineffective or not tolerated. If no other treatment is possible, valproate will be prescribed for you and dispensed under the very strict conditions described below.<br />&bull;Make sure you read the Patient Guide that you will receive from your specialist doctor. Your doctor will discuss the Annual Risk Acknowledgment Form and will ask you to sign it and keep it. You must show it to the pharmacist every time you pick up your medicine, along with the doctor&rsquo;s prescription. This Form certifies that the risks have been explained to you and that you agree to comply with the conditions below. Your pharmacist will also give you a Patient Card to remind you of the risks associated with taking valproate during pregnancy.</strong><br />You must not take DEPAKINE:<br />&bull;if you are pregnant, unless no other epilepsy treatment works for you.<br />&bull;if you are a woman of childbearing age, unless no other epilepsy treatment works for you and you are able to follow all the steps of the Pregnancy Prevention Plan.<br /><em><u>Risks related to taking valproate during pregnancy</u></em><br />&bull;Talk to your specialist doctor immediately if you are planning to have a baby, are pregnant or think you might be pregnant.<br />&bull;Valproate carries a risk for the unborn baby if taken during pregnancy. The higher the dose, the greater the risks; however, all doses carry a risk, including when valproate is used in combination with other medicines to treat epilepsy.<br />&bull;When taken by pregnant women, valproate can cause serious birth defects and may have a harmful effect on the development (intellectual, motor, behavioural) of the growing child.<br />&bull;The most commonly reported birth defects include spina bifida (malformation of the bone of the spinal cord), malformations of the face, upper lip and palate, skull, heart, kidneys, urinary tract and genitals and damage to the limbs, and multiple combined malformations affecting several organs and parts of the body. The birth defects may lead to handicaps, which may be severe.<br />&bull;Hearing disorders or hearing loss have been reported in children exposed to valproate during pregnancy.<br />&bull;Eye malformations have been reported in children exposed to valproate during pregnancy in association with other birth defects. These eye malformations may affect vision.<br />&bull;If you take valproate during pregnancy, you have a higher risk than other women of having a child with birth defects that require medical treatment. Since valproate has been used for many years, it is known that nearly 11 out of 100 babies born to mothers taking valproate have birth defects, compared to 2 to 3 out of 100 babies in the general population.<br />&bull;It is estimated that up to 30&ndash;40% of pre-school children whose mothers took valproate during pregnancy may have problems with early childhood development. Children affected can be slower to walk and/or talk, and/or have a lower IQ than other children, and/or have difficulty with language and/or memory.<br />&bull;Autistic spectrum disorders are more often diagnosed in children exposed to valproate during pregnancy.<br />&bull;There is evidence that children exposed to valproate during pregnancy have an increased risk of developing attention deficit hyperactivity disorder (ADHD).<br />&bull;Before prescribing this medicine to you, your doctor will have explained what might happen to your baby if you become pregnant while taking valproate. If you decide later you want to have a baby you must not stop taking your medicine or your method of contraception until you have discussed this with your doctor.<br />&bull;If you are a parent or a caregiver of a female child treated with valproate, you should contact the doctor once your child using valproate experiences her first monthly period.<br />&bull;Some birth control pills (oestrogen-containing birth control pills) may lower valproate levels in your blood. Make sure you talk to your doctor about the method of contraception that is the most appropriate for you.<br /><strong>Please choose the situation that applies to your case in the list below and read the corresponding paragraph:</strong><br />oI AM STARTING TREATMENT WITH DEPAKINE<br />oI AM TAKING DEPAKINE AND NOT PLANNING TO HAVE A BABY<br />oI AM TAKING DEPAKINE AND PLANNING TO HAVE A BABY<br />oI AM PREGNANT AND I AM TAKING DEPAKINE<br /><strong>I AM STARTING TREATMENT WITH DEPAKINE</strong><br />If this is the first time you have been prescribed DEPAKINE, your specialist doctor will have explained the risks of the treatment for the unborn child if you become pregnant. Once you are able to have a baby, you must use at least 1 effective method of contraception without interruption throughout your treatment with DEPAKINE.<br />Talk to your doctor, gynaecologist or family planning clinic if you need advice on contraception.<br /><strong>Key messages:</strong><br />&bull;Before starting treatment, your doctor will have to make sure that no treatment other than valproate works for you.<br />&bull;Before starting treatment, Your doctor will ask you to do a pregnancy test. Pregnancy must be excluded before start of treatment with Depakine with the result of a pregnancy test, confirmed by your doctor.<br />&bull;You must use at least 1 effective method of contraception (preferably an intrauterine device or a contraceptive implant) or 2 effective methods that work differently (for example, the Pill and a condom) during your entire treatment with DEPAKINE.<br />&bull;You must discuss the appropriate methods of contraception with your doctor. Your doctor will give you information on preventing pregnancy, and may refer you to a specialist for advice on contraception.<br />&bull;You must get regular (at least annual) appointments with a specialist experienced in the management of epilepsy. During this visit your doctor will make sure you are well aware and have understood all the risks and advice related to the use of valproate during pregnancy.<br />&bull;Tell your doctor you want to have a baby before stopping your contraception.<br />&bull;Schedule an urgent appointment with your specialist doctor experienced in the treatment of epilepsy if you are pregnant or think you might be pregnant.<br /><strong>I AM TAKING Depakine AND NOT PLANNING TO HAVE A BABY</strong><br />If you are continuing treatment with DEPAKINE but you are not planning to have a baby make sure you are using at least 1 effective method of contraception without interruption during your entire treatment with DEPAKINE. Talk to your doctor, gynaecologist or family planning clinic if you need advice on contraception.<br /><strong>Key messages:</strong><br />&bull;Your specialist doctor must check regularly (at least once a year) whether any treatment other than valproate works for you.<br />&bull;You must use at least 1 effective method of contraception (preferably an intrauterine device or a contraceptive implant) or 2 effective methods that work differently (for example, the Pill and a condom) during your entire treatment with DEPAKINE.<br />&bull;You must discuss the appropriate methods of contraception with your doctor. Your doctor will give you information on preventing pregnancy, and may refer you to a specialist doctor for advice on birth control.<br />&bull;You must get regular (at least annual) appointments with a specialist doctor experienced in the management of epilepsy. During this visit your doctor will make sure you are well aware and have understood all the risks and advice related to the use of valproate during pregnancy.<br />&bull;Tell your doctor if you want to have a baby before stopping your contraception.<br />&bull;Schedule an urgent appointment with your specialist doctor experienced in the treatment of epilepsy if you are pregnant or think you might be pregnant.<br /><strong>I AM TAKING DEPAKINE AND PLANNING TO HAVE A BABY</strong><br />Babies born to mothers who have been on valproate are at serious risk of birth defects and problems with development which can be seriously debilitating. If you are planning to have a baby, first schedule an appointment with your specialist doctor experienced in the treatment of epilepsy.<br />Do not stop taking DEPAKINE or your contraception until you have discussed this with your doctor. Your doctor will advise you further and refer you to a specialist doctor experienced in the treatment of epilepsy, so that alternative treatment options can be evaluated early on. Your specialist doctor can put several actions in place so that your pregnancy goes as smoothly as possible and any risks to you and your unborn child are reduced as much as possible.<br />Your specialist should do everything possible to stop the DEPAKINE treatment long before you become pregnant, in order to ensure that your illness is stable. In exceptional circumstances when this is not possible, see the following paragraph (&ldquo;I AM PREGNANT AND I AM TAKING Depakine&rdquo;).<br />Ask your doctor about taking folic acid if you are planning to become pregnant. Folic acid can lower the general risk of spina bifida and early miscarriage that exists with all pregnancies. However, it is unlikely that it will reduce the risk of birth defects associated with valproate use.<br /><strong>Key messages:</strong><br />&bull;Do not stop taking DEPAKINE unless your doctor tells you to.<br />&bull;Do not stop using your methods of birth control before you have talked to your doctor and worked together on a plan to ensure your condition is controlled and the risks to your baby are reduced.<br />&bull;First schedule an appointment with your doctor. During this visit your doctor will make sure you are well aware and have understood all the risks and advice related to the use of valproate during pregnancy.<br />&bull;Your specialist doctor should try everything to stop the treatment with DEPAKINE a long time before you become pregnant.<br />&bull;Schedule an urgent appointment with your specialist doctor experienced in the treatment of epilepsy if you are pregnant or think you might be pregnant.<br /><strong>I AM PREGNANT AND I AM TAKING DEPAKINE</strong><br />Babies born to mothers who have been on valproate are at serious risk of birth defects and problems with intellectual and motor development and behavioural disorders which can be seriously debilitating. Do not stop taking DEPAKINE, unless your doctor tells you to as your condition may become worse. Schedule an urgent appointment with your specialist doctor experienced in the management of epilepsy if you are pregnant or think you might be pregnant.<br />&bull;your doctor will advise you further.<br />&bull;your doctor should try everything possible to stop the treatment and assess all the other options for treatment.<br />In the exceptional circumstances when DEPAKINE is the only available treatment option during pregnancy:<br />&bull;Your doctor may refer you to a specialist so that you and your partner receive counselling and support regarding the valproate-exposed pregnancy.<br />&bull;Your specialist doctor will try to decrease the prescribed dose.<br />&bull;You will be closely monitored, both for the treatment of your illness and to monitor the development of your unborn child.<br />&bull;Ask your doctor about taking folic acid. Folic acid can lower the general risk of spina bifida and early miscarriage that exists with all pregnancies. However, it is unlikely that it will reduce the risk of birth defects associated with valproate use.<br />&bull;Before the birth: your doctor will prescribe certain vitamins for you so that this medicine does not cause bleeding during the first few days of your baby&rsquo;s life or bone deformities.<br />&bull;After the birth: an injection of vitamin K may also be prescribed for your baby after birth to prevent bleeding.<br />&bull;In the children: inform the doctor(s) monitoring your child that you were treated with valproate during pregnancy. He or she will implement strict monitoring of your child&rsquo;s neurological development in order to provide your child with specialized care as early as possible if necessary.<br /><strong>Key messages:</strong><br />&bull;Schedule an urgent appointment with your specialist doctor experienced in the treatment of epilepsy if you are pregnant or think you might be pregnant.<br />&bull;Do not stop taking DEPAKINE unless your specialist doctor tells you to.<br />&bull;Your specialist doctor experienced in the treatment of epilepsy must evaluate all of the options for stopping this treatment.<br />&bull;Your specialist doctor must give you complete information about the risks related to taking DEPAKINE during pregnancy, especially the risks of malformations (birth defects) and of development disorders (intellectual, motor and behavioural) in children.<br />&bull;Make sure you are referred to a specialist doctor for prenatal monitoring in order to detect possible occurrences of birth defects.<br />&bull;Inform the doctors who will be monitoring your child that you took DEPAKINE during your pregnancy. They will implement strict monitoring of the child&rsquo;s neurological development.<br /><strong>Important information for men of childbearing age</strong><br /><em><u>Risks related to taking valproate within the 3 months prior to conception</u></em><br />The results of a study comparing fathers treated with lamotrigine or levetiracetam with fathers treated with valproate suggest an increase in the risk of mental and/or motor developmental disorders in children whose fathers were treated with valproate in the 3 months prior to conception.This study does not allow definitive conclusions to be drawn at this stage.<br />As a precautionary measure, pending additional data:<br /><strong>&bull;Do not discontinue your treatment without talking to your doctor.</strong>If you discontinue your treatment, your symptoms may reappear.<br />&bull;An effective method of contraception must be discussed with your doctor, during your treatment and for at least three months after it has been discontinued.<br />&bull;Tell your doctor if you are thinking about having a child. The doctor will discuss the potential risk and possible therapeutic alternatives with you.<br />&bull;If you are going to have a child, contact your doctor to discuss any questions you may have.<br />&bull;You must not donate sperm during treatment with valproate or any of its derivatives, and for at least three months after it has been discontinued.<br />There are no data on this risk of mental and/or motor developmental disorders of children conceived more than three months after the discontinuation of treatment with valproate.<br /><u><strong>Breast-feeding</strong></u><br />You must not breast-feed during treatment with this medicine unless otherwise indicated by your doctor.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Driving and using machines</strong><br />DEPAKINE may cause drowsiness, especially if taken in combination with other antiepileptic drugs or medicines that can increase drowsiness.<br />If you experience this effect or if your condition is not under control yet and you continue to have seizures, you must not drive or operate machinery.<br /><strong>DEPAKINE 500 mg gastro-resistant tablets contain sodium</strong><br />This medicine contains 69 mg sodium (main component of cooking/table salt) in each tablet. This is equivalent to 3.5% of the recommended maximum daily dietary intake of sodium for an adult. You must take this into account if you are on a salt-free or low-salt diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br /><strong>Instructions for proper use</strong><br />DEPAKINE treatment must be started and supervised by a doctor specialized in the treatment of epilepsy. This treatment must not be prescribed in female children, female adolescents or women able to have a baby unless other treatments are ineffective or not tolerated. If no other treatment is possible, valproate will be prescribed for you and dispensed under very strict conditions (given in the Pregnancy Prevention Program). A specialist must re-evaluate the need for treatment at least once per year.<br />Always comply with the dose prescribed by your doctor. Check with your doctor or pharmacist if you are not sure.<br /><u><strong>Posology</strong></u><br />The daily dose will be decided on for you and checked by your doctor.<br />It is generally divided into 2 to 3 doses per day, preferably during meals.<br /><strong>Patients with kidney disorders</strong><br />Your doctor may decide to adjust your dose.<br /><strong>Use in children<br />Children from 6 years of age</strong><br />Depakine is not recommended for children under 6 years of age, as they can have trouble swallowing the tablet and choke. There are other more suitable medicines available.<br /><u><strong>Method of administration</strong></u><br />Always take the tablets whole with a large glass of water.<br />The tablets are gastro-resistant and must not be split or crushed in order to maintain their efficacy.<br /><u><strong>Duration of treatment</strong></u><br />Do not stop taking this medicine without your doctor&rsquo;s advice.<br /><strong>If you take more DEPAKINE 500 mg gastro-resistant tablets than you should</strong><br />Talk to your doctor or go to the emergency room immediately.<br /><strong>If you forget to take DEPAKINE 500 mg gastro-resistant tablets</strong><br />Do not take a double dose to make up for a forgotten dose.<br /><strong>If you stop taking DEPAKINE 500 mg gastro-resistant tablets</strong><br />Do not stop taking DEPAKINE without asking your doctor&rsquo;s advice. Treatment must be stopped gradually. If you stop taking DEPAKINE suddenly or before your doctor asks you to, you will be exposed to a higher risk of seizures.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>Tell your doctor immediately if you notice any of the following serious side effects. You may need urgent medical care:</strong><br />&bull;Problems with balance and coordination, feeling of lethargy or poorer alertness, combined with vomiting. This may be due to an increase in the amount of ammonium in your blood,<br />&bull;liver damage (hepatitis) or pancreas damage (pancreatitis), which may be serious and&nbsp;life<br />-threatening, and that can start suddenly with fatigue, loss of appetite, exhaustion, drowsiness, nausea, vomiting and stomach pain,<br />&bull;Allergic reaction:<br />sudden swelling of the face and/or neck that can cause difficulty breathing and be life-threatening (angioedema),<br />serious allergic reactions (drug hypersensitivity syndrome) including several symptoms such as fever, skin rash, increased lymph node size, liver damage, kidney damage and abnormal blood test results such as an increase in the number of certain white blood cells (eosinophils),<br />&bull;Raised skin rash, sometimes with blisters that can also affect the mouth (erythema multiforme), blisters with detachment of the skin that can rapidly spread to the entire body and be life-threatening (toxic epidermal necrolysis, Stevens-Johnson syndrome).<br /><strong>Other possible side effects:</strong><br />&bull;birth defects and intellectual and motor development disorders (see section 2, &ldquo;Pregnancy, breast-feeding and fertility&rdquo;).<br /><strong>Tell your doctor or pharmacist if any of the following side effects become severe or last longer than a few days; you might need medical treatment:<br />Very common (may affect more than 1 in 10 people):</strong><br />&bull;nausea,<br />&bull;tremor.<br /><strong>Common (may affect up to 1 in 10 people):</strong><br />&bull;at the beginning of treatment: vomiting, stomach ache, diarrhoea,<br />&bull;weight gain,<br />&bull;headache,<br />&bull;drowsiness,<br />&bull;convulsions,<br />&bull;memory disorders,<br />&bull;confusion, aggressiveness, agitation, attention deficit disorders, hallucinations (seeing, hearing or feeling things that are not there),<br />&bull;extrapyramidal disorders (a group of symptoms such as tremor, stiffness of the limbs and difficulty walking)*,<br />&bull;leakage of urine (urinary incontinence),<br />&bull;rapid and uncontrollable eye movements,<br />&bull;hearing loss,<br />&bull;gum disorders (gingival problems), in particular an increase in gum size (gingival hypertrophy),<br />&bull;painful, swollen mouth, mouth ulcers and burning sensation in the mouth (stomatitis),<br />&bull;hair loss,<br />&bull;menstrual problems (irregular menstruation),<br />&bull;bleeding,<br />&bull;nausea or dizziness,<br />&bull;nail and nail bed disorders,<br />&bull;decrease in the number of platelets (thrombocytopenia), decrease in the number of red blood cells (anaemia),<br />&bull;decrease in the amount of sodium in the blood (hyponatremia, syndrome of inappropriate antidiuretic hormone secretion).<br />Uncommon (may affect up to 1 in 100 people):<br />&bull;impaired alertness that may go as far as transient coma, regressing after the dose is decreased or the treatment stopped,<br />&bull;difficulty coordinating movements,<br />&bull;reversible Parkinsonian syndrome*,<br />&bull;sensation of numbness or prickling in the hands and feet,<br />&bull;abnormal hair texture, change in hair colour, abnormal hair growth,<br />&bull;rash or hives on the skin,<br />&bull;excessive hair growth, particularly in women, virilism, acne (hyperandrogenism),<br />&bull;decreased body temperature (hypothermia),<br />&bull;swelling of the extremities (oedema),<br />&bull;amenorrhea (lack of menstrual period),<br />&bull;worsening and increased frequency of convulsions; onset of a different type of convulsion,<br />&bull;breathing difficulty and pain, due to inflammation of the protective membranes of the lungs (pleural effusion),<br />&bull;decrease in the numbers of all blood cells: white blood cells, red blood cells and platelets (pancytopenia), decrease in the number of white blood cells (leukopenia),<br />&bull;cases of bone disorders have been reported, such as the bones becoming more fragile (osteopenia), a decrease in bone mass (osteoporosis) and fractures. Consult your doctor or pharmacist if you are on long-term treatment with an antiepileptic medicine, if you have a history of osteoporosis or if you are taking corticosteroids,<br />&bull;blood vessel inflammation.<br /><strong>Rare (may affect up to 1 in 1,000 people):</strong><br />&bull;male fertility disorders, generally reversible at least 3 months after treatment is discontinued, and possibly reversible after a reduction in the dose. Do not stop your treatment without first talking to your doctor,<br />&bull;abnormal functioning of the ovaries (polycystic ovary syndrome),<br />&bull;behavioural disturbances, increased psychomotor activity, learning disabilities,<br />&bull;auto-immune reaction with painful joints, skin rash and fever (systemic lupus erythematosus),<br />&bull;decreased thyroid gland activity (hypothyroidism),<br />&bull;muscle pain, muscle weakness that may be serious (rhabdomyolysis),<br />&bull;obesity,<br />&bull;involuntary leakage of urine, usually at night (enuresis),<br />&bull;kidney damage (kidney failure, tubulointerstitial nephritis) which may manifest as decreased urine output,<br />&bull;urinating a lot and feeling thirsty (Fanconi syndrome),<br />&bull;increase in the size of red blood cells (macrocytosis), major decrease in the number of white blood cells (agranulocytosis),<br />&bull;reduced production of blood cells (bone marrow aplasia), blood cell production abnormality (myelodysplasia),<br />&bull;decrease in coagulation factors, abnormal blood coagulation test (increase in INR, increase in activated partial thromboplastin time),<br />&bull;decrease in the amount of vitamin B8 (biotin)/biotinidase,<br />&bull;increase in the amount of ammonium in the blood,<br />&bull;double vision,<br />&bull;the gradual onset of memory and mental capacity disorders (cognitive disorders, dementia)*. These problems decrease a few weeks to a few months after treatment is discontinued.<br />Frequency not known:<br />&bull;decreased carnitine level (observed in blood or muscle tests).<br />Do not stop your treatment without first talking to your doctor.<br />*These symptoms can be associated with brain imaging signs (cerebral atrophy).<br /><strong>Additional side effects in children</strong><br />Some side effects of valproate occur more frequently in children or are more serious than in adults. These lead to liver damage, inflammation of the pancreas (pancreatitis), aggression, agitation, disturbance in attention, abnormal behaviour, hyperactivity and learning disorders.<br /><u><strong>Reporting of side effects</strong></u><br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.<br />By reporting side effects you can help provide more information on the safety of this medicine.<br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton.<br />The expiry date refers to the last day of that month.<br />Store below 30&deg;C, protected from moisture.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;The active substance is:<br />&bull;Sodium valproate .................................................................................................................... 500 mg<br />For 1 tablet.<br />&bull;The other ingredients are:<br />Povidone K90, calcium silicate, talc, magnesium stearate, povidone K30, macrogol 400, maize starch, yellow iron oxide, titanium dioxide, cellulose acetate phthalate, diethyl phthalate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medicine is supplied as gastro-resistant tablets.
Boxes of 10 or 40.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder<br />SANOFI WINTHROP INDUSTRIE</strong><br />82, AVENUE RASPAIL<br />94250 GENTILLY<br /><br /><strong>Manufacturer<br />SANOFI AVENTIS S.A.</strong><br />CTRA. C35 LA BATLLORIA A HOSTALRIC, KM 63.09<br />17404 RIELLS I VIABREA<br />(GIRONA)<br />SPAIN</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>الفئة الدوائيّة العلاجيّة: مضاد صرع، كود التَّصنيف التَّشريحي العلاجي الكيميائي (ATC) : N03AG01 .<br />ينتمي ديباكين إلى فئة من الأدوية تُسمّى مضادات الصرع.<br />يُستعمل هذا الدواء لمعالجة الأشكال المختلفة من الصرع لدى البالغين والأطفال فوق عمر الستّ سنوات. يُستعمل لدى الأطفال كذلك للعلاج الوقائي من الاختلاجات المتعلّقة بالحمى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا ينبغي أخذ ديباكين 200 ملغ، أقراص مقاومة للتحلّل في المعدة<br />&bull;إذا كنتِ حاملاً إلاّ إذا لم يكن أيّ علاج آخر للصّرع فعّالاً بالنسبة إليك )راجعي أدناه &quot;الحمل والإرضاع والخصوبة -<br />نصائح مهمّة موجّهة إلى النساء&quot;(،<br />&bull;إذا كنت امرأة في سنّ الإنجاب، إلاّ إذا لم يكن أيّ علاج آخر للصّرع فعّالاً بالنسبة إليك وكنت قادرة على التقيّد بكلّ<br />إجراءات خطّة الوقاية لتجنّب الحمل )راجعي أدناه &quot;الحمل والإرضاع والخصوبة - نصائح مهمّة موجّهة إلى<br />النساء&quot;(.<br />&bull;إذا كنت تعاني من حساسيّة ضدّ المادة الفاعلة في هذا الدواء )فالبروات الصوديوم( أو ضدّ أحد المركّبات الأخرى في<br />هذا الدواء )المذكورة في القسم 6 ،)<br />&bull;إذا كنت تعاني من حساسيّة ضدّ دواء من فئة الفالبروات )ديفالبروات، فالبروميد(،<br />&bull;إذا كنت تعاني من مرض في الكبد )التهاب الكبد الحاد أو المزمن(،<br />&bull;إذا أصبت أنت أو فرد من عائلتك بالتهاب خطير في الكبد، لا سيّما إذا كان مرتبطًا بأخذ دواء،<br />&bull;إذا كنت تعاني من البرفيريّة الكبديّة )وهو مرض وراثي في الكبد(،<br />&bull;إذا كنت تعاني من مشكلة وراثيّة تسبّب اضطرابًا في الميتوكوندريا )مثلاً متلازمة ألبرس-هوتنلوكر(،<br />&bull;إذا كنت تعاني من اضطراب معروف في الأيض، مثل اضطراب في دورة اليوريا )راجع فقرة &quot;تحذيرات<br />واحتياطات&quot;(،<br />&bull;إذا كنت تعاني من نقص غير معالج في الكارنيتين )مرض أيضي نادر جدًّا(،<br />&bull;إذا كنت تتناول في الوقت نفسه :<br />oنبتة سانت جون )وهي نبتة تُستعمل لعلاج الاكتئاب(.<br />تحذيرات واحتياطات<br />قد يؤدي هذا الدواء، في حالات نادرة جدًّا، إلى إصابة الكبد )التهاب الكبد( أو البنكرياس )التهاب البنكرياس(، وذلك قد يكون خطيرًا ويهدد حياتك.<br />سوف يصف لك طبيبك فحوصات دم لكي يراقب بانتظام وظيفة الكبد لديك، بخاصة في الأشهر الستة الأولى من العلاج.<br />أبلغ الطبيب على الفور إذا لاحظت أيًّا من الأعراض التالية:<br />&bull;تعب مفاجئ، فقدان الشهية، إرهاق، نعاس، تورّم الساقين، توعّك عام ،<br />&bull;تقيّؤ متكرر، غثيان، ألم في البط ن والمعدة، تلوّن البشرة أو العينين باللون الأصفر )يرقان(،<br />&bull;إعادة ظهور نوبات الصرع بالرغم من اتّباع العلاج بصورة صحيحة.<br />&bull;يزداد خطر تلف الكبد إذا تم إعطاء ديباكين للأطفال دون سن 3 سنوات، أو للأشخاص الذين يتناولون أدوية أخرى<br />مضادة للصرع في الوقت ذاته، أو للأشخاص الذين يعانون من اضطراب عصبي أو أيضي آخر وأشكال حادة من<br />الصرع .<br />&bull;إذا كنت تعاني، أثناء العلاج بديباكين، أنت أو طفلك من مشاكل في التوازن والتنسيق، أو شعور بالخمول أو انخفاض<br />اليقظة أو القيء، أخبر طبيبك على الفور. قد يكون هذا بسبب زيادة كمية الأمونيوم في الدم .<br />تحدّث إلى طبيبك قبل أخذ هذا الدواء<br />&bull;إذا كنت تعاني من مرض كلوي ) فشل كلوي(.<br />&bull;إذا كنت تعاني من الذئبة الحمامية الجهازية )مرض نادر(.<br />&bull;إذا كنت تعلم أنت أو إذا اشتبه طبيبك في وجود مشكلة وراث يّة ناتجة عن مرض الميتوكوندريا في عائلتك، بسبب خطر تلف الكبد.<br />&bull;إذا اشتُبه في إصابتك باضطرابات أيضيّة، بما في ذلك الاضطرابات الوراثية الناتجة عن نقص إنزيم من نوع<br />&quot;اضطراب دورة اليوريا&quot;، بسبب خطر ارتفاع مستويات الأمونيوم في الدم .<br />&bull; إذا كنت تعاني من مرض نادر )مرض أيضي وراثي( يُسمّ ى &quot; عوز إنزيم كارنيتين بالميتويل ترانسفيراز 2&quot; ، لأنّ<br />لديك خطر متزايد للإصابة باضطرابات عضل يّة خطيرة )انحلال الربيدات(.<br />&bull;إذا كنت تعاني من نقص غذائي في مادة الكارنيتين الموجودة في اللحوم ومنتجات الألبان، وبخاصة عند الأطفال دو ن سن 10 سنوات.<br />&bull;إذا كنت تعاني من نقص في الكارنيتين وكنت تتناول الكارنيتين.<br />&bull;إذا كنت ستخضع لعمليّة جراحيّة، يجب عليك إبلاغ الطاقم الطبي بأنّك تأخذ هذا الدواء.<br />&bull;في بداية العلاج، سوف يتأكد الطبيب من أنك لست حاملاً ومن أنّك تستعملين وسيلة لمنع الحمل )راجعي فقرة<br />&quot;الحمل&quot;(.<br />&bull;كما مع مضادات الصّرع الأخرى، يمكن أن يؤدّي استعمال هذا الدواء إلى تفاقم نوبات الصّرع أو زيادة حدوثها أو<br />يمكن أن تُصاب حتّى ب نوبات من نوع آخر. في هذه الحالة، استشر طبيبك على الفور.<br />&bull;يمكن أن يسبّب هذا الدواء زيادة في الوزن. سوف ينصحك طبيبك باتباع بعض إجراءات الحمية وسوف يراقب وزنك.<br />&bull;لوحظ أيضًا ظهور أفكار مدمّرة للذات أو أفكار انتحارية لدى عدد قليل من المرضى المعالجين بواسطة مضادات<br />الصرع مثل ديباكين. فإذا راودتك أفكار من هذا النوع، اتصل بطبيبك فورًا.<br />&bull;أعلم طبيبك في حالة ظهور عوارض مثل الرجفة أو تيبّس الأطراف وصعوبات في السير )اضطرابات خارج الهرميّة(<br />أو اضطرابات في الذاكرة وفي القدرات الذهنيّة. سيحاول معرفة ما إذا كانت ناجمة ع ن مرض كامن أو عن ديباكي ن<br />200 ملغ، أقراص مقاومة للتحلّل في المعدة. قد يكون من الضروريّ إيقاف العلاج.<br />أعلم طبيبك إذا كان طفلك يأخذ علاجًا آخر مضادًا للصرع أو إذا كان يعاني من مرض عصبيّ أو أيضيّ آخر أو من أشكال حادة من الصّرع.<br />أدوية أخرى وديباكين 200 ملغ، أقراص مقاومة للتحلّل في المعدة<br />قد تغ يّر بعض الأدوية مفعول الفالبروات والعكس صحيح.<br />لا ينبغي عليك مطلقًا أخذ هذا الدواء إذا كنت تأخذ الدواء التالي:<br />&bull;نبتة سانت جون )دواء نباتيّ الأصل يُستعمل لعلاج الاكتئاب(.<br />إلّا إذا أمر الطّبيب أو الصيدلي بغير ذلك، لا ينبغي بك أن تستعمل هذا الدواء إذا كنت تأخذ أو أخذت مؤخّرًا أو قد تأخذ<br />الأدوية التالية:<br />&bull;لاموتريجين )دواء آخر يُستعمل لعلاج نوبات الصرع(؛<br />&bull;أدوية بينيم )كاربابينيم( )مضادات حيويّة مستعملة لعلاج حالات العدوى البكتيريّة(.<br />أعلم طبيبك إذا كنت تأخذ:<br />&bull;الأدوية التي تحتوي على الأسيتازولاميد )أدوية تُستعمل لتخفيض ضغط العين أو مستويات ثاني أكسيد الكربون في الدم( ؛<br />&bull;المضادات الحيويّة )أدوية تحتوي على أزتريونام أو ريفامبيسين(؛<br />&bull;أدوية أخرى مضادة للصرع )أدوية تحتوي على كاربامازيبين، فلبامات، فينيتوين، فوسفينيتوين، بريميدون،<br />فينوباربيتال، روفيناميد، توبيرامات أو زونيساميد(؛<br />&bull;النيموديبين: يمكن أن يزيد ديباكين تأثيرات النيموديبين )دواء يُستعمل للوقاية من المضاعفات التي يمكن أن تحصل بعد<br />نزيف على مستوى الدماغ(؛<br />&bull;أدوية تحتوي على الإستروجينات )بما فيها بعض حبوب منع الحمل(؛<br />&bull;بروبوفول )دواء مخدّر(؛<br />&bull;الأدوية التي تحتوي على زيدوفودين )أدوية تُستعمل لعلاج عدوى فيروس نقص المناعة البشريّة(؛<br />تحدّث إلى طبيبك قبل أخذ هذا الدواء<br />&bull;إذا كنت تعاني من مرض كلوي ) فشل كلوي(.<br />&bull;إذا كنت تعاني من الذئبة الحمامية الجهازية )مرض نادر(.<br />&bull;إذا كنت تعلم أنت أو إذا اشتبه طبيبك في وجود مشكلة وراث يّة ناتجة عن مرض الميتوكوندريا في عائلتك، بسبب خطر تلف الكبد.<br />&bull;إذا اشتُبه في إصابتك باضطرابات أيضيّة، بما في ذلك الاضطرابات الوراثيّة الناتجة عن نقص إنزيم من نوع<br />&quot;اضطراب دورة اليوريا&quot;، بسبب خطر ارتفاع مستويات الأمونيوم في الدم .<br />&bull; إذا كنت تعاني من مرض نادر )مرض أيضي وراثي( يُسمّ ى &quot; عوز إنزيم كارنيتين بالميتويل ترانسفيراز 2&quot; ، لأنّ<br />لديك خطر متزايد للإصابة باضطرابات عضل يّة خطيرة )انحلال الربيدات(.<br />&bull;إذا كنت تعاني من نقص غذائي في مادة الكارنيتين الموجودة في اللحوم ومنتجات الألبان، وبخاصة عند الأطفال دو ن سن 10 سنوات.<br />&bull;إذا كنت تعاني من نقص في الكارنيتين وكنت تتناول الكارنيتين.<br />&bull;إذا كنت ستخضع لعمليّة جراحيّة، يجب عليك إبلاغ الطاقم الطبي بأنّك تأخذ هذا الدواء.<br />&bull;في بداية العلاج، سوف يتأكد الطبيب من أنك لست حاملاً ومن أنّك تستعملين وسيلة لمنع الحمل )راجعي فقرة<br />&quot;الحمل&quot;(.<br />&bull;كما مع مضادات الصّرع الأخرى، يمكن أن يؤدّي استعمال هذا الدواء إلى تفاقم نوبات الصّرع أو زيادة حدوثها أو<br />يمكن أن تُصاب حتّى ب نوبات من نوع آخر. في هذه الحالة، استشر طبيبك على الفور.<br />&bull;يمكن أن يسبّب هذا الدواء زيادة في الوزن. سوف ينصحك طبيبك باتباع بعض إجراءات الحمية وسوف يراقب وزنك.<br />&bull;لوحظ أيضًا ظهور أفكار مدمّرة للذات أو أفكار انتحارية لدى عدد قليل من المرضى المعالجين بواسطة مضادات<br />الصرع مثل ديباكين. فإذا راودتك أفكار من هذا النوع، اتصل بطبيبك فورًا.<br />&bull;أعلم طبيبك في حالة ظهور عوارض مثل الرجفة أو تيبّس الأطراف وصعوبات في السير )اضطرابات خارج الهرميّة(<br />أو اضطرابات في الذاكرة وفي القدرات الذهنيّة. سيحاول معرفة ما إذا كانت ناجمة ع ن مرض كامن أو عن ديباكي ن<br />200 ملغ، أقراص مقاومة للتحلّل في المعدة. قد يكون من الضروريّ إيقاف العلاج.<br />أعلم طبيبك إذا كان طفلك يأخذ علاجًا آخر مضادًا للصرع أو إذا كان يعاني من مرض عصبيّ أو أيضيّ آخر أو من أشكال حادة من الصّرع.<br />أدوية أخرى وديباكين 200 ملغ، أقراص مقاومة للتحلّل في المعدة قد تغيّر بعض الأدوية مفعول الفالبروات والعكس صحيح.<br />لا ينبغي عليك مطلقًا أخذ هذا الدواء إذا كنت تأخذ الدواء التالي:<br />&bull;نبتة سانت جون )دواء نباتيّ الأصل يُستعمل لعلاج الاكتئاب(.<br />إلّا إذا أمر الطّبيب أو الصيدلي بغير ذلك، لا ينبغي بك أن تستعمل هذا الدواء إذا كنت تأخذ أو أخذت مؤخّرًا أو قد تأخذ<br />الأدوية التالية:<br />&bull;لاموتريجين )دواء آخر يُستعمل لعلاج نوبات الصرع(؛<br />&bull;أدوية بينيم )كاربابينيم( )مضادات حيويّة مستعملة لعلاج حالات العدوى البكتيريّة(.<br />أعلم طبيبك إذا كنت تأخذ:<br />&bull;الأدوية التي تحتوي على الأسيتازولاميد )أدوية تُستعمل لتخفيض ضغط العين أو مستويات ثاني أكسيد الكربون في الدم( ؛<br />&bull;المضادات الحيويّة )أدوية تحتوي على أزتريونام أو ريفامبيسين(؛<br />&bull;أدوية أخرى مضادة للصرع )أدوية تحتوي على كاربامازيبين، فلبامات، فينيتوين، فوسفينيتوين، بريميدون،<br />فينوباربيتال، روفيناميد، توبيرامات أو زونيساميد(؛<br />&bull;النيموديبين: يمكن أن يزيد ديباكين تأثيرات النيموديبين )دواء يُستعمل للوقاية من المضاعفات التي يمكن أن تحصل بعد<br />نزيف على مستوى الدماغ(؛<br />&bull;أدوية تحتوي على الإستروجينات )بما فيها بعض حبوب منع الحمل(؛<br />&bull;بروبوفول )دواء مخدّر(؛<br />&bull;الأدوية التي تحتوي على زيدوفودين )أدوية تُستعمل لعلاج عدوى فيروس نقص المناعة البشريّة(؛<br />تمّت الإفادة لدى الأطفال المعرّضين للفالبروات خلال فترة الحمل عن مشاكل في السمع أو الصمم.<br />&bull;تمّت الإفادة لدى الأطفال المعرّضين للفالبروات خلال فترة الحمل عن تشوّهات في العينيْن بالاشتراك مع تشوّهات<br />خلقيّة أخرى. يمكن أن تؤثّر هذه التشوّهات في العينيْن على البصر.<br />&bull;إذا كنت تأخذين الفالبروات خلال فترة الحمل، يكون خطر إنجابك طفلاً مصابًا بتشوّهات تتطلّب علاجًا طبيًّا أعلى من الخطر الذي تواجهه النساء الأخريات. بما أنّ الفالبروات يُستعمل منذ سنوات كثيرة، أُثبت أنّ ما يقارب 11 طفل من أصل 100 من الأطفال المولودين من أمّهات معالجات بالفالبروات يُصابون بتشوّهات، مقابل 2 إلى 3 أطفال من أصل 100 من الأطفال بين عامة السكّان.<br />&bull;يُقدّر أنّ لغاية 30 إلى 40 % من الأطفال في مرحلة ما قبل المدرسة الذين أخذت أمّهاتهم الفالبروات خلال فترة<br />الحمل، يعانون من مشاكل نموّ في مرحلة طفولتهم المبكرة. الأطفال المعنيّون يتأخّرون أكثر في السّير و/أو في<br />الكلام، و/أو يكون معدّل ذكائهم أضعف من الأطفال الآخرين، و/أو يعانون من صعوبة في تعلم اللغات و/أو التذكُّر&nbsp;<br />&bull;يتمّ تشخيص اضطرابات طيف التوحّد أكثر لدى الأطفال المعرّضين للفالبروات خلال فترة الحمل.<br />&bull;تشير بيانات إلى أنّ خطر الإصابة باضطراب نقص الانتباه/فرط النشاط أعلى لدى الأطفال المعرّضين للفالبروات خلال<br />فترة الحمل.<br />&bull;قبل وصف هذا الدواء لك، يجب أن يكون طبيبك قد شرح لكِ المخاطر المحتملة على طفلك في حالة الحمل خلال فترة<br />أخذ الفالبروات. وفي حال قررت الحمل في فترة لاحقة، لا ينبغي عليك إيقاف علاجك أو وسيلة منع الحمل التي<br />تعتمدينها من دون أن تكوني تحدّثت عن الأمر مع طبيبك.<br />&bull;إذا كنت والدًا/والدة فتاة أو كنت تعتني/تعتنين بفتاة تُعالج بالفالبروات، يجب عليك الاتصال بالطبيب الأخصّائي ما أن تأتي دورتها الشهريّة الأولى.<br />&bull;يمكن أن تخفّض بعض حبوب منع الحمل )حبوب تحتوي على الإستروجينات ( معدّلات الفالبروات في دمك. يجب<br />التحدّث إلى الطبيب لتحديد وسيلة منع الحمل المناسبة لك.<br />الرجاء اختيار الوضع الذي يناسب حالتك من القائمة أدناه وقراءة الفقرة المناسبة:<br />oأبدأ العلاج بديباكين<br />oآخذ ديباكين ولا أنوي الحمل<br />oآخذ ديباكين وأنوي الحمل<br />oأنا حامل وآخذ ديباكين<br />أبدأ العلاج بديباكين<br />إذا كان ديباكين يوصف لكِ للمرّة الأولى، يجب أن يكون طبيبك الأخصّائي قد شرح لكِ مخاطر العلاج التي تواجه الجنين<br />في حالة الحمل. إذا كنتِ في سنّ الإنجاب، يجب أن تحرصي على استعمال وسيلة منع حمل فعّالة واحدة على الأقلّ بدون<br />توقّف طيلة مدّة علاجك بديباكين .<br />للحصول على معلومات حول منع الحمل، استشيري الطبيب العام أو الطبيب النسائي أو مركز تخطيط عائلي.<br />رسائل رئيسيّة:<br />&bull;قبل البدء بالعلاج، سوف يتأكّد الطبيب من عدم وجود أيّ علاج غير الفالبروات ممكن لك.<br />&bull;سوف يطلب منك طبيبك إجراء فحص حمل قبل أن تبدأي بأخذ هذا الدواء . يجب أن تؤكّد النتيجة التي يراها طبيبك أنّك لست حاملاً عندما تبدأين علاجك بديباكين.<br />&bull;يجب عليك أن تستعملي وسيلة منع حمل فعّالة واحدة على الأقلّ )يُفضّل استعمال جهاز داخل الرحم أو وسيلة منع حمل عن طريق الزرع( أو وسيلتين فعّالتين تعملان بطريقة مختلفة )مثلاً حبّة منع حمل هورمونيّة وواقِ ذكريّ( طيلة مدّة علاجك بديباكين.<br />&bull;يجب عليك أن تناقشي وسائل منع حمل مناسبة مع طبيبك. سوف يزوّدك طبيبك بمعلومات حول منع الحمل ويمكن أن يوجّهك إلى أخصّائيّ سوف يعطيك نصائح تتعلّق بمنع الحمل.<br />&bull;يجب عليك أن تستشيري بشكل منتظم )مرّة واحدة في السنة على الأقلّ( طبيبًا أخصّائيًا لديه خبرة في علاج الصرع.<br />عند هذه الاستشارة، سوف يتأكّد طبيبك من أنّك تدركين المخاطر ومن أنّك فهمت المعلومات المرتبطة بمخاطر أخذ الفالبروات خلال فترة الحمل.<br />&bull;إذا كنت ترغبين في الحمل، تحدّثي إلى طبيبك قبل إيقاف وسيلة منع الحمل التي تستعملينها.<br />&bull;إذا كنتِ حاملاً أو كنت تعتقدين نفسك كذلك، خذي موعدًا على الفور مع طبيبك الأخصّائيّ الذي لديه خبرة في علاج<br />الصرع.<br />آخذ ديباكين ولا أنوي الحمل<br />إذا كنت تواصلين العلاج بديباكين وكنت لا تنوين الحمل، تأكّدي من استعمال وسيلة منع حمل واحدة على الأقلّ بدون توقّف طيلة مدّة علاجك بديباكين . للحصول على معلومات حول منع الحمل، استشيري الطبيب العام أو الطبيب النسائي أو مركز تخطيط عائلي.<br />رسائل رئيسيّة:<br />&bull;سوف يتأكّد الطبيب الأخصّائيّ بشكل منتظم )مرّة واحدة في السنة على الأقلّ( من عدم وجود أيّ علاج غير الفالبروات ممكن لك.<br />&bull;يجب عليك أن تستعملي وسيلة منع حمل فعّالة واحدة على الأقلّ )يُفضّل استعمال جهاز داخل الرحم أو وسيلة منع حمل<br />عن طريق الزرع( أو وسيلتين فعّالتين تعملان بطريقة مختلفة )مثلاً حبّة منع حمل هورمونيّة وواقِ ذكريّ( طيلة مدّة<br />علاجك بديباكين.<br />&bull;يجب عليك أن تناقشي وسائل منع حمل مناسبة مع طبيبك. سوف يزوّدك طبيبك بمعلومات حول منع الحمل ويمكن أن يوجّهك إلى أخصّائيّ سوف يعطيك نصائح تتعلّق بمنع الحمل.<br />&bull;يجب عليك أن تستشيري بشكل منتظم )مرّة واحدة في السنة على الأقلّ( طبيبًا أخصّائيًا لديه خبرة في علاج الصرع.<br />عند هذه الاستشارة، سوف يتأكّد طبيبك من أنّك تدركين المخاطر ومن أنّك فهمت المعلومات المرتبطة بمخاطر أخذ الفالبروات خلال فترة الحمل.<br />&bull;إذا كنت ترغبين في الحمل، تحدّثي إلى طبيبك قبل إيقاف وسيلة منع الحمل التي تستعملينها.<br />&bull;إذا كنتِ حاملاً أو كنت تعتقدين نفسك كذلك، خذي موعدًا على الفور مع طبيبك الأخصّائيّ الذي لديه خبرة في علاج<br />الصرع.<br />آخذ ديباكين وأنوي الحمل<br />يواجه الأطفال المولودون من أمّهات معالجات بالفالبروات خطرًا كبيرًا للإصابة بتشوّهات وباضطرابات في النموّ يمكن أن<br />تسبّب لهم إعاقات كبيرة. إذا كنت تنوين الحمل، خذي أوّلاً موعدًا مع طبيبك الأخصّائي الذي لديه خبرة في علاج الصّرع.<br />لا تتو قّفي عن أخذ ديباكين أو استعمال وسيلة منع الحمل قبل أن تتحدّثي بالأمر مع طبيبك. سوف يزوّدك طبيبك بنصائح<br />إضافيّة وسوف يوجّهك إلى طبيب أخصّائيّ لديه خبرة في علاج الصّرع لكي يتمكّن من أن يقيّم في الوقت المناسب<br />العلاجات الممكنة الأخرى. يمكن أن يتخذ الطبيب الأخصّائيّ تدابير مختلفة لكي يسير حملك على ما يرام ولكي تكون<br />المخاطر عليك وعلى طفلك محدودة قدر الإمكان.<br />يجب على طبيبك الأخصّائيّ بذل جهده لإيقاف هذا العلاج بديباكين، قبل وقت طويل من حملك بغية التأكّد من استقرار<br />مرضك. للحالات الاستثنائيّة التي يكون فيها هذا الأمر مستحيلا ، راجعي الفقرة التالية )&quot;أنا حامل وآخذ ديباكين&quot;(.<br />إذا كنتِ تنوين الحمل، اسألي طبيبك الأخصّائي حول أخذ حمض الفوليك. فأخذ مكمّلات حمض الفوليك، يمكن أن يخفّض<br />خطر السنسنة المشقوقة والإجهاض المبكر الذي يمكن أن يحصل مع كلّ حمل. ولكن من غير المرجّح أن يخفّض خطر<br />التشوّهات المرتبطة باستعمال الفالبروات.<br />رسائل رئيسيّة:<br />&bull;لا تتوقّفي عن أخذ ديباكين بدون أن يكون طبيبك قد طلب ذلك منك.<br />&bull;لا تتوقّفي عن استعمال وسائل منع الحمل التي تستعملينها قبل أن تناقشي الأمر مع طبيبك الأخصّائي وقبل أن تتفقا معًا<br />على علاج لكيّ تتأكّدا من أن مرضك تحت السيطرة وأنّ المخاطر على طفلك محدودة.<br />&bull;خذي أوّلاً موعدًا مع طبيبك الأخصّائي. عند هذه الاستشارة، سوف يتأكّد طبيبك من أنّك تدركين المخاطر ومن أنّك<br />فهمت المعلومات المرتبطة بمخاطر أخذ الفالبروات خلال فترة الحمل.<br />&bull;سيبذل طبيبك الأخصائي جهده لإ يقاف هذا العلاج بديباكين، قبل وقت طويل من حملك.<br />&bull;إذا كنتِ حاملاً أو كنت تعتقدين نفسك كذلك، خذي موعدًا على الفور مع طبيبك الأخصّائيّ الذي لديه خبرة في علاج<br />الصرع.<br />أنا حامل وآخذ ديباكين<br />يواجه الأطفال المولودون من أمّهات معالجات بالفالبروات خطرًا كبيرًا للإصابة بتشوّهات وباضطرابات في النمو الفكري<br />والحركي والسلوكي يمكن أن تسبّب لهم إعاقات كبيرة. لا تتوقّفي عن أخذ ديباكين من دون أن يكون طبيبك طلب ذلك؛ فهذا<br />يمكن أن يزيد مرضك سوءًا. إذا كنتِ حاملاً أو كنت تعتقدين نفسك كذلك، خذي موعدًا على الفور مع طبيبك الأخصّائيّ الذي لديه خبرة في علاج الصرع.<br />سوف يعطيك طبيبك نصائح إضافيّة.<br />&bull;يجب أن يبذل طبيبك جهده لإيقاف العلاج وتقييم مجموع العلاجات الأخرى المحتملة.<br />في حالات استثنائيّة، إذا كان ديباكين الخيار العلاجيّ المتاح الوحيد خلال فترة حملك:<br />&bull;يمكن أن يوجّهك طبيبك إلى أخصّائيّ لكي تتلقيا أنت وشريكك المساعدة ونصائح تتعلّق بالحمل مع أخذ فالبروات.<br />&bull;سوف يحاول طبيبك تخفيض الجرعة الموصوفة.<br />&bull;سوف تتمّ متابعتك عن كثب، لعلاج مرضك ولمراقبة نموّ جنينك على حدّ سواء.<br />&bull;اسألي طبيبك حول أخذ حمض الفوليك. فأخذ حمض الفوليك يمكن أن يخفّض خطر السنسنة المشقوقة والإجهاض المبكر الذي يمكن أن يحصل مع كلّ حمل. ولكن من غير المرجّح أن يخفّض خطر التشوّهات المرتبطة باستعمال الفالبروات.<br />&bull;قبل الولادة: سوف يصف لك طبيبك بعض الفيتامينات لتفادي أن يسبّب هذا الدواء نزيفًا خلال الأيّام الأولى من الحياة أو اضطرابات في تشكّل عظم طفلك.<br />&bull;بعد الولادة: يمكن أيضًا وصف حقنة فيتامين ك لطفلك، عند الولادة، لتفادي النزيف.<br />&bull;لدى الطفل: أعلمي الطبيب )الأطبّاء( الذي )الذين( سوف يتابع )يتابعون( طفلك بأنّك عولجت بالفالبروات خلال حملك. سوف يُجري )يُجرون( رصدًا دقيقًا للتطوّر العصبيّ لطفلك بغية تزويده برعاية متخصصة في أقرب وقت ممكن، عند الضرورة.<br />رسائل رئيسيّة:<br />&bull;إذا كنتِ حاملاً أو كنت تعتقدين نفسك حاملاً، خذي على الفور موعدًا مع طبيبك الأخصّائي الذي لديه خبرة في معالجة الصرع.<br />&bull;لا تتوقّفي عن أخذ ديباكين من دون أن يكون طبيبك الأخصّائي طلب ذلك.<br />&bull;يجب على طبيبك الأخصّائي الذي لديه خبرة في علاج الصرع تقييم كلّ الإمكانيّات لإيقاف هذا العلاج.<br />&bull;يجب على طبيبك الأخصّائي تزويدك بالمعلومات الكاملة حول المخاطر المرتبطة بأخذ ديباكين أثناء الحمل، بخاصة<br />مخاطر حصول تشوّهات )تشوّهات خلقيّة( واضطرابات النموّ )الذهنيّ والحركيّ والسلوكيّ( لدى الأطفال .<br />&bull;تأكّدي من أنّه تمّ توجيهك نحو طبيب متخصّص في المراقبة قبل الولادة بهدف كشف أيّ عيوب خلقيّة محتملة.<br />&bull;أعلمي الأطبّاء الذين سوف يتابعون طفلك بأنّك أخذت ديباكين خلال حملك. سوف يُجرون رصدًا دقيقًا للتطوّر العصبيّ لطفلك.<br />معلومات مهمة للرجال القادرين على الإنجاب<br />المخاطر المرتبطة بأخذ الفالبروات خلال الأشهر الثلاثة السابقة للحمل<br />تشير نتائج دراسة تقارن بين الآباء المعالجين بلاموتريجين أو ليفيتيراسيتام والآباء المعالجين بالفالبروات إلى زيادة خطر<br />الإصابة باضطرابات في النمو الذهني و/أو الحركي لدى الأطفال الذين عولجوا آباؤهم بالفالبروات في الأشهر الثلاثة<br />السابقة للحمل. لا تسمح هذه الدراسة باستخلاص استنتاجات نهائية في هذه المرحلة.<br />كإجراء وقائي وبانتظار بيانات إضافية :<br />&bull; لا توقف علاجك دون التحدث إلى طبيبك. إذا أوقفت علاجك، قد تظهر أعراضك مجدّدًا .<br />&bull; يجب مناقشة وسيلة منع حمل فعالة مع طبيبك أثناء علاجك ولمدة ثلاثة أشهر على الأقل بعد إيقافه.<br />&bull; أعلم طبيبك إذا كنت تفكر أن ترزق بطفل. سيناقش الطبيب الخطر المحتمل والبدائل العلاجية المحتملة معك .<br />&bull; إذا كنت سترزق بطفل، اتصل بطبيبك لمناقشة أي أسئلة لديك .<br />&bull; يجب ألا تتبرع بالحيوانات المنوية أثناء العلاج بالفالبروات أو بأي من مشتقاته، ولمدة ثلاثة أشهر على الأقل بعد إيقاف العلاج .<br />لا توجد بيانات حول خطر الإصابة باضطرابات في النمو الذهني و/أو الحركي لدى الأطفال الذين تم الحمل بهم بعد أكثر من ثلاثة أشهر من إيقاف العلاج بالفالبروات.<br /><strong>الإرضاع</strong><br />لا ينبغي عليك أن تُرضعي إذا كنتِ تأخذين هذا الدواء إلاّ إذا أشار الطبيب إلى خلاف ذلك.<br />استشيري الطبيب أو الصيدلي قبل أخذ أيّ دواء.<br /><strong>قيادة السيارات واستعمال الآلات</strong><br />يمكن أن يسبّب ديباكين النعاس بخاصة إذا كنت تأخذ في الوقت ذاته مضاد اختلاج آخر أو دواء يمكن أن يزيد النعاس.<br />إذا تعرّضت لهذا التأثير أو إذا لم يكن مرضك تحت السيطرة بعد وكنت لا تزال تُصاب بنوبات صرع، لا ينبغي عليك قيادة سيّارة أو استعمال آلة.<br /><strong>يحتوي ديباكين 200 ملغ، أقراص مقاومة للتحلل في المعدة على الصوديوم.</strong><br />يحتوي هذا الدواء على 28 ملغ من الصوديوم )المكوّن الرئيسي في ملح الطعام( في القرص الواحد مما يعادل 1.4 % من الكميّة الغذائيّة اليوميّة القصوى من الصوديوم الموصى بها للبالغين. يجب أخذ هذا المحتوى بعين الاعتبار إذا كنت تتبع نظامًا غذائيًا من دون ملح أو قليل الملح.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائمًا على أخذ هذا الدواء بالتقيّد تمامًا بتعليمات طبيبك أو الصيدليّ. تحقق من الطبيب أو الصيدلي في حال الشكّ.<br />تعليمات لاستعمال جيّد<br />يجب أن يبدأ العلاج بديباكين ويراقبه طبيب مختصّ في علاج الصرع. لا ينبغي وصف العلاج للفتيات أو المراهقات أو النساء في سنّ الإنجاب إلاّ في حالة عدم فعاليّة أو عدم تحمّل العلاجات الأخرى. إذا لم يكن علاج آخر ممكنًا، سوف يتمّ وصف الفالبروات لك وصرفه وفقًا لشروط صارمة جدًا )مذكورة في برنامج الوقاية من الحمل(. يجب على أخصّائيّ أن يعيد تقييم ضرورة العلاج مرّة واحدة في السنة على الأقلّ.<br />تقيّد دائمًا بالجرعة التي يصفها طبيبك. في حال الشكّ، استشر الطبيب أو الصيدلي.<br />مقدار الجرعة<br />يحدّد طبيبك الجرعة اليوميّة التي يجب استعمالها ويراقبها فرديًا.<br />تُؤخذ الجرعة عادة من مرّتين إلى ثلاث مرّات في اليوم، ويُفضّل أن تُؤخذ مع الطعام.<br />المرضى الذين يعانون من قصور كلويّ<br />قد يقرّر طبيبك تعديل جرعتك.<br />الاستعمال لدى الأطفال<br />الأطفال ابتداء من عمر الستّ سنوات لا يوصى باستعمال ديباكين لدى الأطفال ما دون الستّ سنوات من العمر لأنّه يمكنهم بلع القرص بطريقة خاطئة وبالتالي الاختناق. توجد أدوية أخرى تناسبهم أكثر.<br />طريقة الاستعمال<br />ابلع الأقراص بالكامل دائمًا مع كوب كبير من الماء.<br />هذا القرص مقاوم للتحلل في المعدة. لا يجب كسره ولا سحقه للحفاظ على فعاليّته الكاملة .<br />مدّة العلاج<br />لا تتوقف عن أخذ هذا الدواء من دون استشارة الطبيب أوّلاً.<br />إذا أخذت جرعة مفرطة من ديباكين 200 ملغ، أقراص مقاومة للتحلل في المعدة<br />اتصل بالطبيب أو بقسم الطوارئ الطبّية على الفور.<br />إذا نسيت أخذ ديباكين 200 ملغ، أقراص مقاومة للتحلل في المعدة<br />لا تأخذ جرعة مضاعفة للتعويض عن الجرعة التي نسيت أخذها .<br />إذا توقّفت عن أخذ ديباكي ن 200 ملغ، أقراص مقاومة للتحلل في المعدة<br />لا تتوقّف عن أخذ ديباكين بدون استشارة طبيبك أوّلاً. يجب إيقاف العلاج تدريجيًا. إذا توقّفت فجأة عن أخذ ديباكين أو قبل أن يطلب طبيبك منك ذلك، سوف يزيد خطر تعرّضك لنوبات صرع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبّب هذا الدواء تأثيرات جانبيّة لا تصيب المرضى كلّهم.<br />أعل م طبيبك على الفور إذا لاحظت أيًّا من التأثيرات الجانبيّة الخطيرة الآتية. فقد تحتاج إلى رعاية طبية عاجلة :<br />&bull;مشاكل ف ي التواز ن والتنسيق، والشعور بالخمول أو ضعف اليقظة ، بالإضافة إلى التقيّؤ. قد يكون هذ ا بسبب زيادة كمية الأمونيوم في دمك ،<br />&bull;إصابة في الكبد )التهاب الكبد( أو البنكرياس )التهاب البنكرياس( مما قد يكون خطيرًا ومهددًا للحياة، ويمكن أن يبدأ فجأة مع تعب وفقدان الشهيّة وإرهاق ونعاس وغثيان وتقيّؤ وألم في البطن.<br />&bull;ارتكاس تحسسي:<br />oتورّم مفاجئ في الوجه و/أو العنق يمكن أن يسبّب صعوبة في التنفّس وقد يهدّد الحياة )أوديما كوينك(،<br />oارتكاس تحسسيّ خطير )تناذر فرط الحساسيّة تجاه الدواء( يتضمّن عدّة أعراض مثل الحمى والطفح الجلدي<br />وتضخّم العقد اللمفاويّة وتلف الكبد وتلف الكلى ونتائج غير طبيعيّة لفحوصات الدم مثل زيادة عدد بعض كريات<br />الدم البيض )الحمضات(.<br />&bull;طفح جلدي مع بثور أحيانًا قد يصيب الفم أيضًا )الحمامى المتشكّلة(، بثور مع انقلاع للجلد يمكن أن ينتشر بسرعة على الجسم كلّه ويمكن أن يهدّد الحياة )تناذر ليل، تناذر ستيفنز جونسون(.<br />تأثيرات جانبيّة أخرى محتملة:<br />&bull;عيوب خلقيّة واضطرابات في النموّ الذهني والحركيّ )راجع في القسم 2 &ndash; فقر ة &quot;الحمل والإرضا ع والخصوبة&quot;(.<br />أخبر طبيبك أو الصيدلي إذا أصبحت أيّ من التأثيرات الجانبية التالية حادّة أو استمرت لفترة أطو ل من بضعة أيام ؛ فقد تحتا ج إل ى علا ج طبي :<br />شائعة جدًا )تُصيب أكثر من شخص واحد من أصل 10 :)<br />&bull;غثيان،<br />&bull;رجفة.<br />شائعة )تُصيب حتّى شخص واحد من أصل 10 :)<br />&bull;في بداية العلاج: تقيّؤ، أوجاع في المعدة، إسهال،<br />&bull;زيادة في الوزن ،<br />&bull;صداع ،<br />&bull;نعاس،<br />&bull;اختلاجات،<br />&bull;اضطرابات في الذاكرة،<br />&bull;تشوّش ذهنيّ، عدائيّة، انفعال، اضطرابات في الانتباه، هلوسات )رؤية أشياء غير موجودة أو سماعها أو الشعور بها(،<br />&bull;اضطرابات خارج الهرميّة )مجموعة من الأعراض مثل الرجفة وتيبّس الأعضاء وصعوبة السير(*،<br />&bull;تسرّب البول )السلس البولي(،<br />&bull;حركات سريعة ولا يمكن التحكّم بها في العينين،<br />&bull;فقدان السمع،<br />&bull;اضطرابات في اللثّة بخاصة زيادة حجم اللثّة )تضخّم اللثّة( ،<br />&bull;ألم وتورّم وتقرّحات في الفم وشعور بحريق في الفم )التهاب الفم(،<br />&bull;تساقط الشعر،<br />&bull;اضطرابات في الدورة الشهريّة )عدم انتظام الحيض( ،<br />&bull;نزف،<br />أحاسيس بالغثيان أو الدوار ،&bull;<br />اضطرابات في الأظافر ومهد الأظافر،<br />&bull;انخفاض عدد الصفيحات )قلّة الصفيحات(، انخفاض عدد الكريات الحمر )فقر دم(،<br />&bull;انخفاض كميّة الصوديوم في الدم )نقص صوديوم الدم، متلازمة الإفراز غير الملائم للهرمون المضاد لإدرار البول(.<br />غير شائعة )تُصيب حتّى شخص واحد من أصل 100 :)<br />&bull;اضطرابات في اليقظة يمكن أن تصل إلى الغيبوبة العابرة، تتراجع بعد تخفيض الجرعة أو إيقاف العلاج،<br />&bull;صعوبة في تنسيق الحركات،<br />&bull;متلازمة باركنسون عكوسة*،<br />&bull;خدر أو تنمّل في اليدين والقدمين،<br />&bull;ملمس غير طبيعي للشعر، تغييرات في لون الشعر، نموّ غير طبيعي للشعر،<br />&bull;طفح بثور أو بقع على الجلد ،<br />&bull;نموّ الشعر الزائد، بخاصة لدى النساء، ترجيل، حب الشباب )فرط الأندروجينية(،<br />&bull;انخفاض حرارة الجسم ،<br />&bull;تورّم الأطراف )أوديما(،<br />&bull;انقطاع الطمث )غياب الدورة الشهريّة(،<br />&bull;زيادة عدد الاختلاجات وخطورتها، ظهور نوبات اختلاجيّة من نوع مختلف،<br />&bull;صعوبة في التنفّس وألم يعود إلى تورّم الغشاء الواقي للرئتين )الانصباب الجنبي(،<br />&bull;انخفاض مجموع خلايا الدم: الكريات البيض والكريات الحمر والصفيحات )قلّة الكريات الشاملة(، انخفاض عدد<br />الكريات البيض )نقص الكريات البيض(،<br />&bull;أفيد عن حالات من الاضطرابات العظميّة تظهر عبر هشاشة العظام )نقص العظام(، انخفاض الكتلة العظميّة )ترقق<br />العظام( وعن كسور.<br />استشر الطبيب أو الصيدلي في حالة العلاج الطويل الأمد بدواء مضاد للصرع، أو في حالة إصابة سابقة بترقق العظام أو أخذ كورتيكوستيريدات،<br />&bull;التهاب الأوعية الدمويّة.<br />نادرة )تُصيب حتّى شخص واحد من أصل 1000 :)<br />&bull;اضطرابات في الخصوبة لدى الرجال تكون عمومًا قابة للزوال على الأقلّ 3 أشهر بعد إيقاف العلاج ومن المحتمل أن تكون قابلة للزوال بعد تخفيض الجرعة. لا توقف علاجك قبل استشارة الطبيب أوّلاً،<br />&bull;خلل في وظيفة المبيضين )متلازمة المبيض المتعدد الكيسات(،<br />&bull;اضطرابات في السلوك، زيادة النشاط النفسي الحركي، صعوبات في التعلّم ،<br />&bull;ارتكاس مناعيّ ذاتيّ مع ألم في المفاصل، طفح جلدي وحمى )ذئبة حمامية منتشرة(،<br />&bull;انخفاض نشاط الغدّة الدرقيّة )قصور الغدّة الدرقيّة( ،<br />&bull;آلام عضليّة وضعف عضلي يمكن أن يكون خطيرًا )انحلال الربيدات(،<br />&bull;بدانة،<br />&bull;تسرّب البول اللاإرادي، عادة في الليل )سلس بولي(،<br />&bull;تضرر الكلى )قصور كلويّ، التهاب الكلية النبيبي الخلالي( قد يظهر على شكل انخفاض في كميّة البول،<br />&bull;كثرة التبوّل والشعور بالعطش )متلازمة فانكوني (،<br />&bull;زيادة حجم كريات الدم الحمر )كبر الكريات(، انخفاض كبير في عدد الكريات البيض )ندرة المحببات(،<br />&bull;فقدان إنتاج خلايا الدم )فقر الدم اللاتنسجي(، إنتاج غير طبيعي لخلايا الدم )خلل التنسج النخاعي( ،<br />&bull;انخفاض عوامل التخثّر، اختبارات تخثّر غير طبيعيّة )ارتفاع INR ، إطالة تنشيط وقت الثرومبوبلاستين الجزئي...(،<br />&bull;انخفاض كميّة الفيتامين ب 8 )بيوتين(/بيوتينيداز،<br />&bull;ارتفاع كميّة الأمونيا في الدم،<br />&bull;ازدواج الرؤية،<br />&bull;اضطرابات في الذاكرة وفي القدرات الذهنيّة تظهر تدريجيًا )اضطرابات معرفيّة، متلازمة العته(*، تخفّ بعد بضعة<br />أسابيع إلى بضعة أشهر من إيقاف العلاج.<br />غير محدّدة معدّل الحصول:<br />&bull; انخفاض في مستويات الكارنيتين )يظهر في اختبارات الدم أو العضلات(.<br />لا توقف علاجك قبل استشارة الطبيب أوّلاً.<br />*يمكن أن تكون هذه الأعراض مرتبطة بعلامات إشعاعيّة على مستوى الدماغ )ضمور الدماغ(.<br />تأثيرات جانبيّة إضافيّة لدى الأطفال<br />تكون بعض التأثيرات الجانبيّة للفالبروات أكثر شيوعًا لدى الأطفال أو أكثر خطورة من البالغين. ويؤدي هذا إلى إصابة<br />الكبد، والتهاب البنكرياس، والعدائيّة، والانفعال، واضطراب في الانتباه، وسلوك غير طبيعيّ وفرط الحركة واضطراب في<br />التعلّم.<br />الإبلاغ عن التأثيرات الجانبيّة<br />إذا شعرت بأيّ تأثير جانبيّ، أعلم الطبيب أو الصيدليّ. ينطبق هذا أيضًا على أيّ تأثير جانبيّ غير مذكور في هذه النشرة.<br />بالإبلاغ عن التأثيرات الجانبيّة، تساهم في تزويد المزيد من المعلومات حول سلامة الدواء.<br />للإبلاغ عن أيّ عارض )أعراض( جانبيّ )ة(:<br />&bull;المملكة العربية السعودية:<br />-المركز الوطني للتّيقُّظ والسلامة الدوائية :<br />oفاكس: +966-11-205-7662<br />oاتّصل بالمركز الوطني للتّيقُّظ والسلامة الدوائية على: +966-11-2038222 ، أرقام داخليّة<br />2317-2356-2353-2354-2334-2340 .<br />oالرقم المجاني: 8002490000<br />oالبريد الإلكتروني: npc.drug@sfda.gov.sa<br />oالموقع الإلكتروني: www.sfda.gov.sa/npc<br />&bull;سانوفي للتّيقُّظ والسلامة الدوائية: KSA_Pharmacovigilance@sanofi.com</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ هذا الدواء بعيدًا عن نظر ومتناول الأطفال.<br />لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة.<br />يشير تاريخ انتهاء الصلاحيّة إلى اليوم الأخير من الشهر المذكور.<br />يُحفظ في درجة حرارة ما دون 30 درجة مئويّة بعيدًا عن الرطوبة.<br />لا ترمِ الأدوية في مصرف المياه أو مع النفايات المنزلية العادية. اطلب من الصيدلي التخلّص من الأدوية التي لم تعد تستعملها، فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا يحتوي ديباكين 200 ملغ، أ قراص مقاومة للتحلل في المعدة<br />&bull;<br />المادة الفاعلة هي :<br />فالبروات الصوديوم........................................................................................................... 200 ملغ<br />للقرص الواحد .<br />&bull;<br />المركّبات الأخرى هي:<br />بوفيدون K90 ، سيليكات الكالسيوم، طلق، ستيارات المغنيزيوم، بوفيدون K30 ، ماكروغول 400 ، نشاء الذرة، ثاني<br />أكسيد التيتانيوم، فتالات أسيتات السلليلوز، فتالات الإثيل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو ديباكين 200 ملغ، أقرا ص مقاومة للتحلل في المعدة ومحتويات العلبة الخارجيّة<br />يأتي هذا الدواء على شكل أقراص مقاومة للتحلل في المعدة<br />علبة من 10 ، 40 أو 100 .<br />قد لا تكون الأحجام كلّها مسوّقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل رخصة التسويق<br />SANOFI-AVENTIS FRANCE<br />82, AVENUE RASPAIL<br />94250 GENTILLY<br /><br />المصنّع<br />SANOFI AVENTIS S.A.<br />CTRA. C35 LA BATLLORIA A HOSTALRIC, KM 63.09<br />17404 RIELLS I VIABREA<br />(GIRONA)<br />SPAIN</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اكتوبر 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DEPAKINE 500 mg gastro-resistant tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sodium valproate ........................................................................................................................... 500 mg
Per one gastro-resistant tablet.
This medicinal product contains sodium (see section 4.4).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro-resistant tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>In adults</strong></u>: either as monotherapy or in combination with another antiepileptic treatment:<br />&bull;Treatment of generalised epilepsy: clonic, tonic, tonic-clonic seizures, absences, myoclonic, atonic seizures, and Lennox-Gastaut syndrome.<br />&bull;Treatment of partial epilepsy: partial seizures with or without secondary generalisation.<br /><u><strong>In children</strong></u>: either as monotherapy or in combination with another antiepileptic treatment:<br />&bull;Treatment of generalised epilepsy: clonic, tonic, tonic-clonic seizures, absences, myoclonic, atonic seizures, and Lennox-Gastaut syndrome.<br />&bull;Treatment of partial epilepsy: partial seizures with or without secondary generalisation.<br /><u>In children:</u><br />&bull;Prevention of recurrence of seizures after one or more febrile convulsions, presenting the criteria for complicated febrile convulsions, in the absence of efficacy of intermittent prophylaxis with benzodiazepines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Female children and women of childbearing potential</u><br />Valproate treatment should be initiated and monitored by a specialist doctor experienced in the management of epilepsy.<br />Valproate should not be used in female children and women of childbearing potential, except in cases of ineffectiveness or intolerance to other treatments. In this case, valproate should be prescribed and dispensed in accordance with the valproate pregnancy prevention programme (see sections 4.3 and 4.4).<br />This form is not suitable for children under 6 years of age (risk of choking).<br />Of the oral pharmaceutical forms, the syrup, oral solution and PR granule forms are particularly suitable for administration in children under 11 years of age.<br />Posology<br />Mean dosage per 24 hours:<br />&bull;Infants and children: 30 mg per kg (syrup, oral solution or prolonged-release granule forms should preferably be used).<br />&bull;Adolescents and adults: 20 to 30 mg per kg (tablets, chrono tablets or prolonged-release granule forms should preferably be used).<br />Patients with kidney failure<br />In patients with kidney failure, it may be necessary to decrease the dosage, and in patients undergoing haemodialysis, it may be necessary to increase it. Sodium valproate is dialysable (see section 4.9). The dosage should be modified according to the patient&rsquo;s clinical monitoring (see section 4.4).<br />Method of administration<br />For oral use.<br />The daily dose is to be administered in 2 or 3 doses, preferably with a meal.<br />Start of treatment<br />&bull;If the patient is already being treated and is receiving other antiepileptic medicinal products, gradually introduce sodium valproate to reach the optimal dose in about two weeks, then possibly reduce the associated treatments, depending on the control obtained;<br />&bull;If the patient is not receiving other antiepileptic medicinal products, the dosage should be preferably increased in successive increments every 2 or 3 days so as to achieve the optimal dosage in about one week;<br />&bull;If necessary, the combination of other antiepileptic medicinal products should be carried out gradually (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •Pregnant women, unless there is no suitable therapeutic alternative (see sections 4.4 and 4.6).
•Women of childbearing potential, unless all conditions of the pregnancy prevention programme are met (see sections 4.4 and 4.6).
•History of hypersensitivity to valproate, divalproate, valpromide, or to any of the excipients listed in section 6.1.
•Acute hepatitis.
•Chronic hepatitis.
•Personal or family history of severe hepatitis, in particular medicine-induced.
•Hepatic porphyria.
•Patient with known urea cycle disorders (see section 4.4).
•Patient with primary, uncorrected, systemic carnitine deficiency (see section 4.4 “Patients at risk of hypocarnitinaemia”).
•Valproate is contraindicated in patients with known mitochondrial disorders, caused by mutations in the nuclear gene encoding the mitochondrial enzyme polymerase gamma (POLG), e.g., Alpers-Huttenlocher syndrome and in children under the age of two years suspected of having a POLG-related disorder (see section 4.4).
•Combination with St. John’s Wort (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special warnings<br />Pregnancy prevention programme<br />Valproate is a potent teratogen resulting in a high risk of congenital malformations and&nbsp;neurodevelopmental disorders in children exposed in utero to valproate (see section 4.6). Valproate should not be used in female children and women of childbearing potential, except in cases of ineffectiveness or intolerance to other treatments. If no other treatment is possible, follow the pregnancy prevention programme below.<br />DEPAKINE is contraindicated in the following cases:<br />&bull;In pregnant women, unless there is no suitable therapeutic alternative (see sections 4.3 and 4.6).<br />&bull;In women of childbearing potential, unless all conditions of the pregnancy prevention programme are met (see sections 4.3 and 4.6).<br />Conditions of the pregnancy prevention programme<br />The prescriber must ensure that:<br />&bull;individual situations are assessed on a case-by-case basis, involving the patient in the discussion, in order to secure her commitment, to discuss treatment options, and to ensure that the patient has understood the risks and the steps needed to reduce those risks;<br />&bull;the risk of pregnancy is assessed in all female patients;<br />&bull;the patient fully understands and is aware of the risks of birth defects and neurodevelopmental disorders, including the magnitude of these risks for children exposed in utero to valproate;<br />&bull;the patient understands the need to perform a pregnancy test before starting treatment and during treatment, as needed;<br />&bull;the patient has been counselled on contraception, and is able to comply with the need to use effective contraception (for details, see the &ldquo;Contraception&rdquo; subsection of this box), without interruption, throughout the duration of treatment with valproate;<br />&bull;the patient understands the need for a specialist physician experienced in the management of epilepsy to regularly (at least annually) review the treatment;<br />&bull;the patient understands the need to consult her doctor as soon as she considers pregnancy in order to discuss it in due time, and to seek alternative treatment options before conception. This should be done before stopping contraception;<br />&bull;the patient understands the need to urgently consult her physician in the event of pregnancy;<br />&bull;the patient has received the patient information leaflet;<br />&bull;the patient acknowledged having understood the risks and necessary precautions associated with the use of valproate (annual care agreement form).<br />These conditions also concern women who are not sexually active, unless the prescriber considers that there are indisputable reasons indicating that there is no risk of pregnancy.<br />Female children<br />&bull;Prescribers should ensure that parents/caregivers of a female child understand the need to contact the specialist physician as soon as the female child using valproate has her first period.<br />&bull;The prescriber should ensure that parents/carers of a female child having her first period receive full information on the risks of congenital malformations and neurodevelopmental disorders, including the extent of these risks for children exposed to valproate in utero.<br />&bull;For patients who have had their first period, the prescribing specialist physician should reassess the need for treatment with valproate annually, and consider all alternative treatment options. If valproate is the only appropriate treatment, the need to use effective contraception and all other conditions of the pregnancy prevention programme should be discussed. Every effort should be made by the specialist physician to switch to alternative treatment in female children. This should be done before puberty or adulthood.<br />Pregnancy test<br />Pregnancy must be excluded before initiating treatment with valproate. Valproate treatment should&nbsp;not be initiated in women of childbearing potential without obtaining a negative pregnancy test (plasma pregnancy test with a sensitivity of at least 25 mIU/ml), confirmed by a healthcare professional, in order to eliminate any possibility of unintended use of the product during pregnancy. This pregnancy test should be repeated at regular intervals during treatment.<br />Contraception<br />Women of childbearing potential who receive valproate have to use effective contraception continuously and throughout the duration of valproate treatment. These patients should receive comprehensive information on pregnancy prevention, as well as contraceptive counselling if they are not using effective contraception.<br />At least one effective method of contraception (preferably a method whose effectiveness does not depend on the user, such as an intra-uterine contraceptive device or an implant), or two complementary methods of contraception including a barrier method, must be used. When choosing the method of contraception, individual situations should be considered on a case-by-case basis, involving the patient in the discussion to ensure her commitment and compliance with the chosen measures. All advice on effective contraception should be followed, even in the case of amenorrhoea.<br />Medicinal products containing oestrogen<br />Concomitant use with medicinal products containing oestrogen, including hormonal contraceptives containing oestrogen, may potentially lead to a decrease in the efficacy of valproate (see section 4.5). Prescribers should monitor the clinical response (epilepsy control) to initiation or discontinuation of medicinal products containing oestrogen.<br />Conversely, valproate does not reduce the effectiveness of hormonal contraceptives.<br />Annual evaluation of the treatment by a specialist physician<br />The specialist physician should reassess, at least annually, the valproate treatment to check whether it is still the most appropriate treatment for the patient. The specialist physician should discuss the annual care agreement form when the treatment is initiated and at each annual assessment and should ensure that the patient has understood its content. The care agreement form must be duly completed and signed by the prescriber and the patient (or the patient&rsquo;s legal representative).<br />Pregnancy planning<br />In women planning a pregnancy, a specialist physician experienced in the management of epilepsy should reassess treatment with valproate, and consider all alternative treatment options. Every effort should be made to switch to an appropriate alternative treatment prior to conception and before contraception is stopped (see section 4.6). If a therapy change is not possible, the patient should receive additional advice regarding the risks that valproate presents for the unborn child, in order to help her make an informed decision regarding her family planning.<br />In case of pregnancy<br />If a woman using valproate becomes pregnant, she should be referred immediately to a specialist physician to reassess valproate treatment, and to consider alternative options. Patients whose pregnancies have been exposed to valproate, as well as their partners, should be referred to a physician specialised or experienced in teratology for evaluation and advice (see section 4.6).<br />The pharmacist should ensure that:<br />&bull;the patient card is given with each dispensation of valproate, and that patients understand its content;<br />&bull;patients are advised not to stop valproate treatment on their own, and to contact a specialist physician immediately if they are planning or suspect pregnancy.<br />Information leaflets<br />To help healthcare professionals and patients avoid foetal exposure to valproate, the marketing authorisation holder should provide them with information leaflets to reinforce the teratogenicity (congenital malformations) and foetotoxicity (neurodevelopmental disorders) warnings for valproate and to provide recommendations to women of childbearing potential regarding the use of valproate, as well as details on the pregnancy prevention programme. A patient card and patient information leaflet should be provided to all patients using valproate.<br />An annual care consent form must be used and duly completed and signed at the time of treatment initiation and during each annual reassessment of valproate treatment by the specialist physician and the patient (or her legal representative).<br />Use in men of childbearing age<br />Data from a retrospective study conducted on Scandinavian registries suggest an increase in the risk of neurodevelopmental disorders in children whose fathers were treated with valproate in the 3 months prior to conception, compared to those whose fathers were treated with lamotrigine or levetiracetam. The limitations of this study do not allow conclusions to be drawn about this potential risk at this stage, and additional data are necessary.<br />As a precautionary measure, the prescriber should inform patients able to father children of this potential risk. The prescriber must discuss the following with them:<br />&bull;the need to implement effective contraceptive measures during treatment and for at least three months after treatment discontinuation,<br />&bull;the possibility of therapeutic alternatives for patients planning to conceive a child,<br />&bull;not to donate sperm during treatment with valproate, and for at least three months after discontinuing it (see section 4.6).<br />The risk of neurodevelopmental disorders for children conceived by men stopping valproate more than three months before conception is not known.<br />Worsening of seizures<br />As with other antiepileptic medicinal products, valproate may be followed, instead of improvement, by reversible worsening of seizure frequency and severity (including status epilepticus) or the development of new seizure types in the patient. In case seizures worsen, the patient should be advised to consult their physician immediately (see section 4.8). These seizures can be distinguished from those that may occur during a pharmacokinetic interaction (see section 4.5), toxicity (hepatopathy or encephalopathy &ndash; see sections 4.4 and 4.8) or overdose.<br />As this medicinal product transforms into valproic acid in the body, it should not be combined with other medicinal products undergoing this same transformation in order to avoid a valproic acid overdose (for example: divalproate, valpromide).<br />Severe hepatic damage<br />Conditions of occurrence<br />Liver damage, which is severe and sometimes fatal, has been reported exceptionally.<br />Infants and young children under 3 years of age with severe epilepsy, including epilepsy associated with brain damage, mental retardation and (or) carnitine deficiency a congenital metabolic disease, including mitochondrial disorders, such as carnitine deficiency, urea cycle disorders, POLG mutations (see sections 4.3 and 4.4) or a degenerative disease of genetic origin, are most at risk. Beyond the age of 3 years, the incidence of occurrence decreases significantly and gradually decreases with age.<br />In the vast majority of cases, hepatic damage was observed during the first 6 months of treatment, most often between the 2nd and 12th week and generally during anti-epileptic combination therapy.<br />Suggestive signs<br />Early diagnosis is still mainly clinical. In particular, two types of manifestations which may precede jaundice should be taken into consideration, especially in patients at risk (see &ldquo;Conditions of occurrence&rdquo;):<br />&bull;on the one hand, non-specific general signs that usually appear suddenly such as asthenia, anorexia, depression, somnolence, sometimes accompanied by repeated vomiting and abdominal pain,<br />&bull;on the other hand, a reappearance of epileptic seizures while the treatment is properly followed.<br />It is advisable to inform the patient, or their family if it is a child, that the appearance of such a clinical picture must immediately motivate a consultation. This will include, in addition to the clinical examination, the immediate performance of a liver function panel.<br />Detection<br />Liver function should be monitored before the start of treatment and regularly during the first 6 months of treatment, especially in patients at risk.<br />In the event of a change in the combined treatments known for their liver toxicity (increase in dose or new treatment), laboratory liver monitoring should be repeated (see also section 4.5 on the risk of hepatic damage with salicylates, other anticonvulsants including cannabidiol).<br />Among the standard examinations, tests reflecting protein synthesis and in particular PT (prothrombin time ratio) are the most relevant. Confirmation of an abnormally low prothrombin time ratio, especially if it is accompanied by other laboratory abnormalities (significant decrease in fibrinogen and coagulation factors, increased bilirubin, elevated transaminases &ndash; see section &ldquo;Precautions for use&rdquo;) should lead to discontinuation of treatment with this medicinal product (as a precaution, this also applies to salicylate derivatives if they are co-prescribed, since they use the same metabolic pathway).<br />Pancreatitis<br />Cases of pancreatitis, which is sometimes fatal, have been very rarely reported. They can be observed regardless of age and duration of treatment, as young children seem particularly exposed to this risk.<br />Pancreatitis of an unfavourable course is generally observed in young children, or in patients with severe epilepsy, brain lesions or antiepileptic combination therapy.<br />Liver failure associated with pancreatitis increases the risk of fatal progression.<br />In the event of acute abdominal pain syndrome, such as in case of gastrointestinal disorders such as nausea, vomiting and/or anorexia, it is necessary to suggest the diagnosis of pancreatitis and in case of elevated pancreatic enzymes, interrupt the treatment by implementing the alternative therapeutic measures that are necessary.<br />Suicidal ideation and behaviour<br />Suicidal ideation and behaviour have been reported in patients treated with antiepileptic medicinal products in several indications. A meta-analysis of randomised, placebo-controlled trials on antiepileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The causes of this risk are not known and the available data do not rule out the possibility of an increase of such a risk due to valproate.<br />Therefore, patients should be closely monitored for any signs of suicidal ideation and behaviour, and appropriate treatment should be considered. It must be recommended to patients (and their caregiver) to seek medical advice in the case of the onset of signs of suicidal ideation and behaviour.<br />Patients with known or suspected mitochondrial disease<br />Valproate may trigger or worsen clinical signs of underlying mitochondrial illness caused by mitochondrial DNA mutations, as well as in the nuclear gene encoding the mitochondrial DNA polymerase gamma (POLG).<br />Notably, cases of valproate-induced acute liver failure and related deaths have been reported at a higher rate in patients with hereditary neurometabolic syndromes caused by mutations in the POLG gene, e.g., Alpers-Huttenlocher syndrome.<br />POLG-related disorders should be suspected in patients with a family history of or symptoms suggestive of a POLG-related disorder including, but not limited to, unexplained encephalopathy, refractory epilepsy (focal, myoclonic), status epilepticus on presentation, developmental delays, psychomotor regression, sensorimotor axonal neuropathy, myopathy, cerebellar ataxia, ophthalmoplegia, or a complicated migraine with occipital aura. For a diagnostic evaluation of such disorders, a test for POLG mutations should be performed, according to current clinical practice (see section 4.3).<br />Interaction with other medicinal products<br />Taking this medicinal product in combination with lamotrigine and/or penems (carbapenems) is not recommended (see section 4.5).<br />Cognitive or extrapyramidal disorders<br />Cognitive or extrapyramidal disorders may be associated with scans showing cerebral atrophy. The clinical picture may thus be confused with dementia-like diseases or Parkinson&rsquo;s disease. These disorders are reversible upon discontinuation of treatment (see section 4.8).<br />Information related to the presence of sodium<br />This medicinal product contains 69 mg sodium per tablet, equivalent to 3.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult. This should be taken into account for patients adhering to a strict low-sodium diet.<br />Precautions for use<br />Perform a liver function panel before the start of treatment (see section 4.3), then perform periodic monitoring during the first 6 months, especially in patients at risk (see section 4.4, &ldquo;Severe hepatic damage &ndash; Detection&rdquo;).<br />It should be emphasised that, as with most antiepileptic medicinal products, we can observe, particularly at the start of treatment, a moderate, isolated and transient increase of transaminases, without any clinical signs.<br />In this case, it is advisable to perform a more complete laboratory panel (prothrombin time ratio, in particular), to potentially reconsider the dosage and to reinforce controls based on the evolution of the parameters.<br />A haematology exam (FBC including platelets, bleeding time and coagulation panel) is recommended prior to treatment, then at 15 days and at the end of treatment, as well as before a surgical procedure and in the case of haematoma or spontaneous bleeding (see section 4.8).<br />In patients with kidney failure, the increase in free serum concentrations of valproic acid should be taken into account and the dosage reduced accordingly.<br />Urea cycle disorders and risk of hyperammonaemia<br />This medicinal product is contraindicated in patients with urea cycle enzyme deficiency. A few cases of hyperammonaemia associated with stupor or coma have been described in these patients (see sections 4.3 and 4.4, &ldquo;Patients at risk of hypocarnitinaemia and severe liver damage&rdquo;).<br />Patients at risk of hypocarnitinaemia<br />Administration of valproate may trigger the onset or worsening of hypocarnitinaemia, which may lead to hyperammonaemia (which may cause hyperammonaemic encephalopathy). Other symptoms, such as liver toxicity, hypoketotic hypoglycaemia, myopathy including cardiomyopathy, rhabdomyolysis, Fanconi syndrome, have been observed, mainly in patients with risk factors for hypocarnitinaemia or pre-existing hypocarnitinaemia. The patients with an increased risk of symptomatic hypocarnitinaemia when they are treated with valproate are: patients with metabolic disorders, including carnitine-related mitochondrial disorders (see also section 4.4, Patients with known or suspected mitochondrial disease and urea cycle&nbsp;disorders and risk of hyperammonaemia), patients with an impaired nutritional intake of carnitine, patients under 10 years of age and patients treated concomitantly with pivalate-conjugated medicinal products or with other anti-epileptics.<br />Patients should be instructed to immediately report any signs of hyperammonaemia, such as ataxia, altered consciousness, vomiting. Carnitine supplementation should be considered when symptoms of hypocarnitinaemia are observed.<br />Patients with primary systemic carnitine deficiency and corrected hypocarnitinaemia can only be treated with valproate if the benefits of treatment with valproate outweigh the risks incurred for these patients and in the absence of an alternative treatment. In these patients, carnitine monitoring should be implemented.<br />Patients with underlying carnitine palmitoyltransferase II (CPT II) deficiency should be cautioned about the increased risk of rhabdomyolysis when taking valproate. Carnitine supplementation should be considered in these patients. See also sections 4.5, 4.8 and 4.9.<br />Although this medicinal product is recognised as only exceptionally leading to immune system disorders, its use in a subject with disseminated lupus erythematosus should be weighed based on the benefit/risk balance.<br />At the initiation of treatment, patients must be informed of the risk of weight gain and of appropriate measures, primarily dietary, which must be taken in order to minimise it.<br />The excretion of valproate is essentially urinary, partly in the form of ketone bodies; ketonuria testing may give false positives in diabetic patients.<br />Alcohol consumption is not recommended for the duration of the treatment with DEPAKINE.<br />Children<br />In children under 3 years of age, it is recommended that valproate be used as monotherapy only, after assessing the therapeutic benefit in relation to the risk of hepatopathy and pancreatitis in patients in this age group prior to initiation of treatment (see section 4.4 &ldquo;Severe hepatic damage&rdquo; and also section 4.5).<br />In children under 3 years of age, avoid simultaneously prescribing salicylates, given the risk of hepatotoxicity (also see section 4.4) and the risk of haemorrhage.<br />In children with a history of unexplained hepato-gastrointestinal disorders (anorexia, vomiting, bout of cytolysis), bout of lethargy or coma, intellectual disability or in the case of a family history of neonatal deaths or deaths during childhood, metabolic tests and in particular NPO and postprandial ammonia plasma level tests must be performed before any treatment with valproate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraindicated combinations<br />+ St John&rsquo;s Wort<br />Risk of decreased plasma concentrations and the efficacy of the anticonvulsant.<br />Inadvisable combinations<br />+ Lamotrigine<br />Increased risk of serious skin reactions (Lyell&rsquo;s syndrome).<br />Also, an increase in lamotrigine plasma concentrations (decrease in its hepatic metabolism by sodium valproate).<br />If the combination is necessary, close clinical monitoring should be carried out.<br />+ Penems (carbapenems)<br />Risk of the onset of seizures due to a rapid decrease in plasma concentrations of valproic acid, which may become undetectable.<br />Administration of valproic acid in combination with carbapenems resulted in a decrease in plasma concentrations of valproic acid of 60 to 100% in approximately two days. Due to the rapid onset and the significance of the decrease in plasma concentrations, the simultaneous administration of carbapenems in patients stabilised on valproic acid that cannot be monitored should therefore be avoided (see section 4.4).<br />Combinations requiring precautions for use<br />+ Acetazolamide<br />Increased hyperammonaemia, with increased risk of encephalopathy.<br />Regular clinical and laboratory monitoring.<br />+ Aztreonam<br />Risk of the onset of seizures due to decreased plasma concentrations of valproic acid.<br />Clinical monitoring, plasma assays and possible anticonvulsant dose adjustment during and after treatment with the anti-infective medicinal product.<br />+ Carbamazepine<br />Increase in plasma concentrations of the active metabolite of carbamazepine with signs of overdose. Also, a decrease in plasma concentrations of valproic acid due to an increase in its hepatic metabolism by carbamazepine.<br />Clinical monitoring, plasma assays and dosage adjustment of both anticonvulsants.<br />+ Felbamate<br />Increased plasma concentrations of valproic acid, with risk of overdose.<br />Clinical monitoring, laboratory tests and possible valproate dosage adjustment during and after treatment with felbamate.<br />+ Medicinal products containing oestrogen, including hormonal contraceptives containing oestrogen<br />Oestrogens are inducers of the isoforms of UDP-Glucuronosyltransferase (UGT) involved in the glucuronidation of valproate and may increase its clearance; this may result in decreased serum concentration of valproate and potentially decreased efficacy (see section 4.4). Consider monitoring serum concentrations of valproate.<br />Conversely, due to the lack of enzyme-inducing effect, valproate does not decrease the efficacy of oestro-progestogens in women on hormonal contraception.<br />+ Metamizole<br />Metamizole may decrease serum concentrations of valproate when co-administered, which may lead to a potential decrease in the clinical efficacy of valproate.<br />Monitoring of clinical response (seizure control or mood control) and considering monitoring of serum concentrations of valproate, if applicable.<br />+ Methotrexate<br />In some cases, a significant decrease in serum valproate levels is reported after administration of methotrexate, with the occurrence of convulsions.<br />Prescribers should monitor clinical response (seizure control or mood control) and consider appropriate monitoring of serum valproate levels.<br />+ Nimodipine (oral and by extrapolation, injectable)<br />Risk of increased plasma concentrations of nimodipine by 50%. Therefore, the dosage of nimodipine should be reduced in case of hypotension.<br />+ Phenobarbital, and by extrapolation primidone<br />Increased hyperammonaemia, with increased risk of encephalopathy.<br />Regular clinical and laboratory monitoring.<br />+ Phenytoin, and by extrapolation fosphenytoin<br />Increased hyperammonaemia, with increased risk of encephalopathy.<br />Regular clinical and laboratory monitoring.<br />+ Propofol<br />Possible increase in blood concentrations of propofol. A dose reduction of propofol should be considered when combined with valproate.<br />+ Rifampicin<br />There is a risk of seizures due to an increase in the hepatic metabolism of valproate by rifampicin.<br />Clinical and laboratory monitoring and possible anticonvulsant dosage adjustment during and after treatment with rifampicin.<br />+ Rufinamide<br />Possible increase in rufinamide concentrations, especially in children weighing less than 30 kg.<br />In children weighing less than 30 kg: do not exceed the total dose of 600 mg/d after the titration period.<br />+ Topiramate<br />Increased hyperammonaemia, with increased risk of encephalopathy.<br />Regular clinical and laboratory monitoring.<br />+ Zidovudine<br />Risk of increased undesirable effects, particularly haematological effects, of zidovudine due to a decrease in its metabolism by valproic acid.<br />Regular clinical and laboratory monitoring. A complete blood count to screen for anaemia should be performed during the first two months of the combination.<br />+ Zonisamide<br />Increased hyperammonaemia, with increased risk of encephalopathy.<br />Regular clinical and laboratory monitoring.<br />Other forms of interaction<br />+ Lithium<br />DEPAKINE has no effect on serum lithium.<br />+ Risk of liver damage<br />Concomitant use of salicylates should be avoided in children under 3 years of age due to the risk of hepatic toxicity (see section 4.4).<br />Simultaneous use of valproate and other anticonvulsants increases the risk of liver damage, especially in young children (see section 4.4).<br />Use in combination with cannabidiol increases the incidence of elevated transaminases. In clinical trials in patients of any age receiving cannabidiol at doses of 10&ndash;25 mg/kg and valproate simultaneously, an increase in ALT of more than 3 times the upper normal limit was reported in 19% of patients. Appropriate liver monitoring should be performed when valproate is used in combination with other potentially hepatotoxic anticonvulsants, including cannabidiol. Dose reductions or therapy cessation should be considered in case of significant abnormalities in hepatic parameters (see section 4.4).<br />+ Pivalate-conjugated medicinal products<br />Concomitant administration of valproate and pivalate-conjugated medicinal products (such as cefditoren pivoxil, adefovir dipivoxil, pivmecillinam and pivampicillin) should be avoided due to the increased risk of decreased carnitine (see section 4.4 Patients at risk of hypocarnitinaemia). Patients for whom concomitant administration cannot be avoided should be closely monitored for any signs or symptoms of hypocarnitinaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valproate is contraindicated (see sections 4.3 and 4.4):<br />&bull;during pregnancy, unless there is no appropriate alternative therapy;<br />&bull;in women of childbearing potential, unless all conditions of the pregnancy prevention programme are met.<br />Use in men of childbearing age: see section 4.4 &laquo;Warnings&raquo; and paragraph &laquo;Male of childbearing age&raquo; below.<br />Pregnancy<br />Teratogenicity and neurodevelopmental effects<br />The use of valproate, whether as monotherapy or in combination with other antiepileptic medicinal products, is frequently associated with abnormal pregnancy outcomes. The available data show an increased risk of major congenital malformations and neurodevelopmental disorders, both when valproate is used as monotherapy as well as in combination therapy, compared to the population not exposed to valproate. Valproate has been shown to cross the placental barrier in animals and humans (see section 5.2). In animals, teratogenic effects have been demonstrated in mice, rats and rabbits (see section 5.3).<br />&bull;Congenital malformations<br />A meta-analysis (including registries and cohort studies) showed that approximately 11% of children born to mothers with epilepsy treated with valproate monotherapy during pregnancy had major congenital malformations. This is greater than the risk of major malformations encountered in the general population (approximately 2&ndash;3%).<br />The risk of major congenital malformations in children exposed in utero to antiepileptic combination therapy including valproate is higher than the risk associated with antiepileptic combination therapy without valproate.<br />This risk is dose-dependent during monotherapy with valproate, and the available data suggest that it is dose-dependent during combination therapy with valproate. However, no threshold dose excluding this risk could be determined.<br />Available data show an increased incidence of minor and major malformations. The most common malformations encountered include neural tube defects (between 2 and 3%), facial dysmorphisms, cleft&nbsp;lips and cleft palates, craniostenosis, renal, urogenital, and heart malformations (including hypospadias), malformations of the limbs (including bilateral radial aplasia) and polymalformative syndromes affecting different parts of the body.<br />In utero exposure to valproate may also lead to hearing impairment or deafness due to nose and/or ear malformations (side effect), and/or direct toxicity to auditory function. Cases describe unilateral and bilateral hearing impairment or deafness. Developments were not reported for all cases. When developments were reported, there was no recovery in the majority of cases.<br />In utero exposure to valproate may lead to eye malformations (including coloboma and microphthalmia), which have been reported in conjunction with other congenital malformations. These eye malformations may affect vision.<br />&bull;Neurodevelopmental disorders<br />Studies highlight that valproate leads to an increased risk of neurodevelopmental disorders in children exposed in utero. The risk of neurodevelopmental disorders (including autism) appears to be dose-dependent when valproate is used as monotherapy, but the available data do not make it possible to determine a dose excluding this risk.<br />When valproate is administered in combination with other antiepileptic medicinal products during pregnancy, the risks of neurodevelopmental disorders in children were also significantly increased, compared to children from the general population or those born to untreated epileptic mothers.<br />The risk period for these effects is uncertain and the possibility of a risk throughout the pregnancy cannot be excluded. When valproate is administered as monotherapy, studies in nursery school-age children exposed to valproate in utero show that up to 30&ndash;40% of them experience developmental delays in early childhood, such as delays in the acquisition of speech and walking, reduced intellectual abilities, reduced verbal (speaking and understanding) abilities, as well as memory disturbances.<br />The intelligence quotient (IQ) of primary school-age children (6 years) exposed to valproate in utero was on average 7 to 10 points lower than that of children exposed to other antiepileptic medicinal products. Although the role of confounding factors cannot be excluded, it is proven that this decrease in IQ observed in children exposed in utero is independent of maternal IQ.<br />Data on the course of these long-term disorders are limited.<br />Available data from a study based on the population show that children exposed to valproate in utero have an increased risk of having autism spectrum disorders (about 3 times more common) and childhood autism (about 5 times more common), compared to the unexposed population in the study.<br />Available data from another study based on the population show that children exposed to valproate in utero have an increased risk of developing attention deficit/hyperactivity disorder (ADHD) (about 1.5 times more common), compared to the unexposed population in the study.<br />Women of childbearing potential<br />In women of childbearing potential, DEPAKINE treatment should not be used, except in cases of ineffectiveness or intolerance to other treatments. If no other treatment is possible, DEPAKINE can only be initiated if the pregnancy prevention programme is followed (see section 4.4), including:<br />&bull;not being pregnant (negative plasma pregnancy test with a sensitivity of at least 25 mIU/ml at treatment initiation and at regular intervals during treatment);<br />&bull;using at least one effective method of contraception;<br />&bull;being informed of the risks of using valproate during pregnancy.<br />In these women, the benefit/risk balance should be carefully reassessed at regular intervals during treatment (at least annually).<br />Medicinal products containing oestrogen:&nbsp;<br />Medicinal products containing oestrogen, including hormonal contraceptives containing oestrogen, may increase the clearance of valproate, which may result in decreased serum concentrations of valproate and potentially decreased efficacy (see sections 4.4 and 4.5).<br />If pregnancy is planned:<br />In women planning a pregnancy, a specialist physician experienced in the management of epilepsy should reassess treatment with valproate, and consider all alternative treatment options. Every effort should be made to switch to an appropriate alternative treatment prior to conception and before contraception is stopped (see section 4.4). If a therapy change is not possible, the patient should receive additional advice regarding the risks that valproate presents for the unborn child, in order to help her make an informed decision regarding her family planning.<br />Folic acid supplementation before and at the beginning of pregnancy may decrease the risk of developing neural tube defects inherent in any pregnancy. For information, the available data do not show any preventive action of folic acid on valproate-related malformations.<br />Pregnant women<br />Valproate used in the treatment of epilepsy is contraindicated during pregnancy, unless there is no appropriate therapeutic alternative (see sections 4.3 and 4.4).<br />In the event of pregnancy in a woman using valproate, she must be immediately referred to a specialist physician in order to consider all alternative treatment options. During pregnancy, tonic-clonic epilepsy and status epilepticus with hypoxia in the mother can lead to serious or even fatal consequences for the mother and the unborn child.<br />If, in exceptional circumstances, despite the known risks associated with the use of valproate during pregnancy, and after careful evaluation of alternative treatments, valproate absolutely had to be maintained to control epilepsy in a pregnant woman:<br />&bull;it is essential to use the minimum effective dose<br />&bull;it is recommended that the daily dosage be divided into several smaller doses during the day. The use of a sustained release formulation may be preferable to other formulations in order to avoid plasma peaks (see section 4.2).<br />All patients whose pregnancies have been exposed to valproate, and their partners, should be referred to a physician specialised or experienced in teratology for evaluation and counselling regarding the exposed pregnancy:<br />&bull;specialised prenatal monitoring should be initiated to detect possible abnormalities involving the neural tube or other malformations;<br />Before delivery<br />Perform a coagulation panel including in particular platelet count, fibrinogen assay and coagulation time (activated partial thromboplastin time, aPTT) in the mother before delivery.<br />Risk in the newborn child<br />&bull;Very rare cases of bleeding tendency have been reported in newborn children of mothers treated with valproate during pregnancy. This bleeding tendency is related to thrombocytopenia, hypofibrinogenemia, and/or a decrease in other coagulation factors. Afibrinogenemia has also been reported and can be fatal. However, this syndrome must be distinguished from a vitamin K factor deficiency induced by phenobarbital and enzyme inducers. A normal haemostasis assessment in the mother does not exclude haemostasis abnormalities in the newborn child. Therefore, at birth, newborn children should undergo an assessment including a platelet count, fibrinogen assay, coagulation factors and tests.<br />&bull;Cases of hypoglycaemia have been reported in newborn children whose mothers were treated with valproate during the third trimester of pregnancy.<br />&bull;Cases of hypothyroidism have been reported in newborn children whose mothers were treated with valproate during pregnancy.<br />&bull;Withdrawal syndrome (particularly agitation, irritability, hyperexcitability, nervousness, hyperkinesia, muscle tone disorders, tremors, seizures, and feeding disorders) may occur in newborn children whose mothers were treated with valproate during the third trimester of pregnancy.<br />Postnatal/child follow-up<br />In the case of exposure during pregnancy, a close follow-up of neurobehavioral development in the child is to be started and appropriate management should be implemented as early as possible if needed.<br />Men of childbearing age:<br />Risk for the children of fathers treated with valproate<br />Data from a retrospective study conducted on Scandinavian registries suggest an increase in the risk of neurodevelopmental disorders in children (from 0 to 11 years) whose fathers were treated with valproate in the 3 months prior to conception, compared to those whose fathers were treated with lamotrigine or levetiracetam.<br />The limitations of this study do not allow conclusions to be drawn about this potential risk at this stage, and additional data are necessary.<br />As a precautionary measure, the prescriber should inform patients of childbearing age of this potential risk.<br />The prescriber must discuss the following with them:<br />&bull;the need for effective contraceptive measures during treatment, and for at least three months after discontinuing it,<br />&bull;the possibility of therapeutic alternatives for patients who are planning to conceive a child,<br />&bull;do not donate sperm during treatment with valproate and for at least three months after stopping treatment (see section 4.4).<br />The risk of neurodevelopmental disorders for children conceived by men stopping valproate more than three months before conception is not known.<br />Breast-feeding<br />Valproate is excreted in human milk at a concentration between 1% and 10% of maternal serum levels. Haematological disorders have been observed in breastfed newborns/infants of treated women (see section 4.8).<br />The decision to discontinue breast-feeding or to discontinue DEPAKINE therapy should take into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.<br />Fertility<br />Cases of amenorrhoea, polycystic ovaries and increased testosterone levels have been reported in women treated with valproate (see section 4.8). In men, the administration of valproate may also impair fertility (reduced sperm mobility in particular) (see section 4.8). In some cases, these fertility disorders are reversible after at least 3 months of therapy cessation. In a limited number of cases, it has been reported that a significant dose reduction is likely to improve fertility. However, in other cases, the reversibility of these male fertility disorders is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Attention is drawn, particularly in vehicle drivers and machine operators, to the risk of somnolence, particularly in cases of anticonvulsant combination therapy or combination with other medicinal products that may increase somnolence.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Classification of expected frequencies:&nbsp;<br />very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1 000 to &lt; 1/100); rare (1/10 000 to &lt; 1/1 000); very rare (&lt; 1/10 000); not known (cannot be estimated from the available data).<br />Congenital, familial and genetic disorders<br />&bull;Congenital malformations, neurodevelopmental disorders (see sections 4.4 and 4.6).<br />Blood and lymphatic system disorders<br />&bull;Common: anaemia, thrombocytopenia.<br />Cases of dose-dependent thrombocytopenia, usually discovered systematically and without clinical impact, have been described.<br />In the case of asymptomatic thrombocytopenia, if the platelet count and disease control allow for this, simply reducing the dose of this medicinal product most often results in the regression of this thrombocytopenia.<br />&bull;Uncommon: leukopenia, pancytopenia.<br />&bull;Rare: general aplasia bone marrow or pure red cell aplasia, agranulocytosis, macrocytic anaemia, macrocytosis.<br />Investigations<br />&bull;Common: weight gain*.<br />&bull;Rare: decrease in at least one coagulation factor, abnormal coagulation tests (such as prolonged prothrombin time, prolonged activated partial thromboplastin time, prolonged thrombin time, increased INR) (see sections 4.4 and 4.6), vitamin B8 deficiency (biotin)/biotinidase deficiency.<br />*as weight gain is a risk factor for polycystic ovarian syndrome, patients&rsquo; weight must be carefully monitored (see section 4.4).<br />Nervous system disorders<br />&bull;Very common: tremors<br />&bull;Common: extrapyramidal disorders**, stupor*, sedation, seizures*, memory disturbance, headache, nystagmus, nausea or dizziness<br />&bull;Uncommon: coma*, encephalopathy*, lethargy*, reversible parkinsonism**, ataxia, paraesthesia<br />&bull;Rare: diplopia, cognitive disorders of insidious and progressive onset (possibly leading to a full clinical picture of dementia) that are reversible a few weeks to a few months after therapy cessation**<br />*Cases of stupor or lethargy, sometimes leading to transient coma (encephalopathy) have been observed during treatment with valproate, resolving upon therapy cessation or after a dose reduction. These conditions are most likely to occur during combination therapy (with phenobarbital or topiramate in particular) or after a sudden increase in the dose of valproate.<br />**These symptoms may be associated with scans showing cerebral atrophy.<br />Ear and labyrinth disorders<br />&bull;Common: hearing loss.<br />Respiratory, thoracic and mediastinal disorders<br />&bull;Uncommon: pleural effusion.<br />Gastrointestinal disorders<br />&bull;Very common: nausea.<br />&bull;Common: vomiting, gum disorders (mainly gingival hyperplasia), stomatitis, epigastric pain, diarrhoea that may occur in some patients at the start of treatment, but which usually resolve after a few days without interruption of treatment.<br />&bull;Uncommon: pancreatitis, which can be fatal and requires early discontinuation of treatment (see section 4.4).<br />Renal and urinary disorders<br />&bull;Common: urinary incontinence.<br />&bull;Uncommon: renal failure.<br />&bull;Rare: enuresis, tubulointerstitial nephritis, Fanconi syndrome.<br />Skin and subcutaneous tissue disorders<br />&bull;Common: transient and/or dose-dependent hair loss, nail and nail bed disorders.<br />&bull;Uncommon: angioedema, skin reactions, capillary disorders (such as abnormal hair texture, changes in hair colour, abnormal hair growth).<br />&bull;Rare: Lyell&rsquo;s syndrome, Stevens-Johnson syndrome, erythema multiforme, DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome, or drug-induced hypersensitivity syndrome.<br />Endocrine disorders<br />&bull;Uncommon: syndrome of inappropriate antidiuretic hormone secretion (SIADH), hyperandrogenism (hirsutism, virilism, acne, androgenic alopecia and/or increased levels of androgens).<br />&bull;Rare: hypothyroidism (see section 4.6).<br />Metabolism and nutrition disorders<br />&bull;Common: hyponatraemia.<br />&bull;Rare: hyperammonaemia* (see section 4.4), obesity.<br />*Isolated and moderate hyperammonaemia without changes in liver laboratory tests may be observed, especially in the case of combination therapy, and should not cause treatment interruption.<br />However, cases of hyperammonaemia with neurological symptoms (possibly leading to coma) have also been reported, requiring additional investigations (see sections 4.3 and 4.4: &ldquo;Urea cycle disorders and risk of hyperammonaemia and Patients at risk of hypocarnitinaemia&rdquo;).<br />&bull;Not known: hypocarnitinaemia (see sections 4.3 and 4.4).<br />Neoplasms benign, malignant and unspecified (incl. cysts and polyps)<br />&bull;Rare: Myelodysplastic syndrome.<br />Vascular disorders<br />&bull;Common: haemorrhage (see sections 4.4 and 4.8).<br />&bull;Uncommon: skin vasculitides, mainly leukocytoclastic vasculitis.<br />General disorders and administration site conditions<br />&bull;Uncommon: hypothermia, non-severe peripheral oedema.<br />Hepatobiliary disorders<br />&bull;Common: hepatopathy (see section 4.4).<br />Reproductive system and breast disorders<br />&bull;Common: menstrual irregularity.<br />&bull;Uncommon: amenorrhoea.<br />&bull;Rare: male fertility disorders, (see section 4.6), polycystic ovaries.<br />Musculoskeletal and connective tissue disorders<br />&bull;Uncommon: decreased bone mineral density, osteopaenia, osteoporosis and fractures in patients receiving long-term treatment with DEPAKINE. The mechanism of action of DEPAKINE on bone metabolism is not known.<br />&bull;Rare: acute systemic lupus erythematosus (see section 4.4), rhabdomyolysis (see section 4.4).<br />Psychiatric disorders<br />&bull;Common: confusional state, hallucinations, aggressiveness*, agitation*, impairment of attention*.<br />&bull;Rare: abnormal behaviour*, psychomotor hyperactivity*, learning disabilities*.<br />*These reactions are mostly seen in the paediatric population.<br />Paediatric population<br />The safety profile of valproate in the paediatric population is comparable to that in adults, but some undesirable effects are more serious, or are mainly seen in the paediatric population. There is a particular risk of severe hepatic damage in infants and young children, especially before the age of 3 years. Young children also have a particular risk of pancreatitis. These risks decrease with age (see section 4.4). Psychiatric disorders, such as aggression, agitation, impairment of attention, abnormal behaviours, psychomotor hyperactivity and learning disabilities, are mainly observed in the paediatric population.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; SFDA call center : 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The picture of massive acute intoxication usually includes a more or less deep calm coma, with muscle hypotonia, hyporeflexia, miosis, decreased respiratory autonomy, metabolic acidosis, hypotension, and cardiovascular collapse/shock.<br />Some cases of intracranial hypertension associated with cerebral oedema have been described.<br />The measures to be taken in a hospital setting are: gastric emptying if indicated, maintenance of effective diuresis, cardiorespiratory monitoring. In very severe cases, extrarenal purification may be performed.<br />The prognosis of these intoxications is generally favourable, however some deaths have been reported.<br />The presence of sodium in formulations containing valproate may lead to hypernatraemia in the event of overdose.<br />Treatment<br />In the event of a valproate overdose resulting in hyperammonaemia, carnitine may be given IV to attempt to normalise ammonium levels.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ANTIEPILEPTIC, ATC code: N03AG01.<br />Valproate exerts its pharmacological effects primarily in the central nervous system.<br />These anticonvulsant properties are exercised against a wide variety of seizures in animals and epilepsies in humans.<br />Experimental and clinical studies of valproate suggest two types of anticonvulsant action.<br />The first is a direct pharmacological effect in relation to plasma and brain concentrations of valproate.<br />The second is apparently indirect and probably related to persistent valproate metabolites in the brain or with neurotransmitter changes or direct membrane effects. The most generally accepted hypothesis is the gamma-aminobutyric acid (GABA) hypothesis, whose levels increase after administration of valproate.<br />Valproate decreases the duration of intermediate sleep stages with a concomitant increase in NREM sleep.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The different pharmacokinetic studies performed for valproate showed that:<br />&bull;The blood bioavailability of valproate after oral administration is close to 100%.<br />&bull;The volume of distribution is limited primarily to blood and rapidly exchanged extracellular fluids. Valproate diffuses in the CSF and in the brain.<br />&bull;Crossing of the placental barrier (see section 4.6):<br />Valproate crosses the placental barrier in animals and in humans:<br />oin animals, valproate crosses the placenta, in a way that is similar to humans,<br />oIn humans, several publications have evaluated the concentration of valproate in the umbilical cord of newborns at delivery. The serum concentration of valproate in the umbilical cord, representing the serum concentration of valproate in foetuses, was similar or slightly higher than that of the mothers.<br />&bull;Its half-life is from 15 to 17 hours.<br />&bull;Therapeutic efficacy usually requires a minimum serum concentration of 40&ndash;50 mg/l, with a wide range between 40 and 100 mg/l. If higher plasma levels are necessary, the expected benefits must be weighed against the risk of undesirable effects, particularly dose-dependent ones. However, levels that remain above 150 mg/l require a dose reduction.<br />&bull;The steady-state plasma concentration is reached in 3 to 4 days.<br />&bull;The protein binding of valproate is very significant. It is dose-dependent and saturable.<br />&bull;The major pathway of valproate metabolism is glucuronidation (approximately 40%), primarily via UGT1A6, UGT1A9 and UGT2B7.<br />&bull;The excretion of valproate is essentially urinary after metabolism by glucuronidation and beta-oxidation.<br />&bull;The valproate molecule is dialysable, but haemodialysis only affects the free fraction of blood valproate (approximately 10%).<br />&bull;Valproate is not an inducer of enzymes involved in the cytochrome P 450 metabolic system; unlike most other anti-epileptic medicinal products, it does not accelerate its own degradation or that of other substances, such as oestro-progestogens and vitamin K antagonists.<br />Paediatric population<br />From the age of 10 years, children and adolescents have valproate clearances similar to those reported in adults.<br />In paediatric patients under 10 years of age, systemic valproate clearance varies with age. In newborn children and infants up to 2 months of age, valproate clearance is reduced compared to that in adults, and is lowest immediately after birth. In a review of the scientific literature, the half-life of valproate in infants under two months of age showed considerable variability ranging from 1 to 67 hours.<br />In children aged 2 to 10 years, valproate clearance is 50% higher than in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies show that in utero exposure to valproate results in morphological and functional alterations of the auditory system in rats and mice.<br />In vitro, valproate was not mutagenic in bacteria or in mouse lymphoma trials and did not induce DNA repair in primary cultures of rat hepatocytes. However, in vivo, conflicting results were obtained at teratogenic doses depending on the route of administration. After oral administration, the most common route in humans, valproate did not induce chromosomal aberrations in rat bone marrow or major lethal effects in mice. Intraperitoneal injection of valproate increased DNA strand breaks and chromosomal aberrations in rodents. In addition, an increase in sister chromatid exchanges in patients with epilepsy exposed to valproate has been reported in published studies compared to healthy untreated subjects. However, conflicting results were obtained by comparing data from patients with epilepsy treated with valproate with data from untreated patients with epilepsy. The clinical relevance of these DNA/chromosome findings is unknown.<br />Non-clinical data reveal no special hazard for humans based on conventional studies of carcinogenicity.<br />Reproductive toxicity<br />Valproate induced teratogenic effects (malformations of several organ systems) in mice, rats and rabbits.<br />Behavioural abnormalities were reported in first-generation offspring of mice and rats after in utero exposure. Some behavioural changes were also observed in the second generation and were less pronounced in the third generation of mice after acute in utero exposure of the first generation to teratogenic doses of valproate. The underlying mechanisms and clinical relevance of these findings are unknown.<br />In studies on repeated dose toxicity, testicular degeneration/atrophy, abnormal spermatogenesis and a decrease in testicular weight were reported in adult rats and dogs following oral administration of doses of 400 mg/kg/day and 150 mg/kg/day, respectively. The no-observable-adverse-effect levels (NOAELs) associated with testicular effects are 270 mg/kg/day in adult rats and 90 mg/kg/day in adult dogs. On the basis of extrapolations of AUCs (area under curves) in rats and dogs, there might not be a safety margin for humans.<br />In juvenile rats, the decrease in testicular weight was only observed at doses exceeding the maximum tolerated dose (from 240 mg/kg/day intraperitoneally or intravenously) and without associated histopathological changes. No effects on the male reproductive organs were observed at the tolerated doses (up to 90 mg/kg/day). Based on these data, juvenile animals were not considered more likely than adults to have testicular disorders. The clinical relevance of these results regarding the testes for the paediatric population is still unknown.<br />In a fertility study in rats, the administration of valproate at doses of up to 350 mg/kg/day did not impair reproductive performance in males. However, male fertility disorders have been identified as an undesirable effect in humans (see sections 4.6 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Povidone K90, calcium silicate, talc, magnesium stearate, povidone K30, macrogol 400, maize starch, yellow iron oxide, titanium dioxide, cellulose acetate phthalate, diethyl phthalate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For packaging in tubes and pill organisers: 3 years.
For packaging in blister packs: 18 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 or 40 tablets in (polypropylene) tube.<br />10 or 40 tablets in (glass) pill organiser.<br />10 or 40 tablets in (Polyamide/Aluminium/PVC/Aluminium) blisters.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SANOFI-AVENTIS FRANCE
82, AVENUE RASPAIL
94250 GENTILLY

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>